var title_f4_55_4976="Mechanism of bundle branch reentrant ventricular tachycardia";
var content_f4_55_4976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism of bundle branch reentrant ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the reentrant circuit in bundle branch reentrant venticular tachycardia (BBRVT) showing a venticular premature beat that blocks in the right bundle branch (RBB), conducts slowly up the left bundle branch (LBB), activates the bundle of His, and returns antegradely down the RBB. If the RBB has recovered its excitability from the preceding beat, the circuit is completed and the reentrant circuit may become repetitive. The ECG in the inset shows a left bundle branch block pattern in leads I and II.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4976=[""].join("\n");
var outline_f4_55_4976=null;
var title_f4_55_4977="Meglumine antimoniate: International drug information";
var content_f4_55_4977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meglumine antimoniate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Glucantim (IT);",
"     </li>",
"     <li>",
"      Glucantime (BR, ES, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3466651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of leishmaniasis (except",
"     <i>",
"      L. aethiopica",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3466654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.M., I.V.: 20 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: Equivalent to 85 mg of pentavalent antimony/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10495 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4977=[""].join("\n");
var outline_f4_55_4977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302640\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466651\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466652\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466654\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821122\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466655\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4978="Gallium citrate Ga-67: Drug information";
var content_f4_55_4978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gallium citrate Ga-67: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/1/38930?source=see_link\">",
"    see \"Gallium citrate Ga-67: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13176404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13176473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. (based on 70 kg patient): 2-5 mCi (74-185 MBq). For tumors, dose may be 5-10 mCi (185-370 MBq).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13176472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: 0.04-0.07 mCi/kg (1.5-2.6 MBq/kg)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13176405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic imaging of Hodgkin&rsquo;s disease, lymphoma, bronchogenic carcinoma, and inflammatory lesions to identify fevers of unknown origin; nonbacterial infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13176477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13176406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13176452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13176453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13176454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13176455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Instruct patient to interrupt breast-feeding for 1 month following administration of 4 mCi (150 MBq).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Palestro CJ, Brown ML, Forstrom LA, et al, &ldquo;Society of Nuclear Medicine Procedure Guideline for Gallium Scintigraphy in Inflammation,\" 2004. Available at file://interactive.snm.org/docs/Gallium_Scintigraphy_in_Inflammation_v3.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16796 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4978=[""].join("\n");
var outline_f4_55_4978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176404\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176473\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176472\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896332\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896333\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176405\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255250\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176477\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176406\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176452\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176453\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176454\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13176455\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/1/38930?source=related_link\">",
"      Gallium citrate Ga-67: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4979="Sentinel node biopsy PI";
var content_f4_55_4979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Sentinel node biopsy for breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 680px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a sentinel node biopsy for cancer, a doctor:",
"    <br>",
"     1) Injects a blue dye and/or a radioactive substance near the tumor.",
"     <br>",
"      2) If a radioactive substance is used, the doctor uses a probe that detects radiation to find the sentinel lymph nodes. If a blue dye is used, the sentinel lymph node turns blue.",
"      <br>",
"       3) The doctor then removes the sentinel lymph node for testing.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4979=[""].join("\n");
var outline_f4_55_4979=null;
var title_f4_55_4980="Arginine: Drug information";
var content_f4_55_4980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Arginine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/56/35715?source=see_link\">",
"    see \"Arginine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/3/23605?source=see_link\">",
"    see \"Arginine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      R-Gene&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pituitary function test: I.V.: 30 g (300 mL) administered over 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F136617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/3/23605?source=see_link\">",
"      see \"Arginine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pituitary function test: I.V.: 0.5 g/kg/dose administered over 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     R-Gene&reg; 10: 10% [100 mg/mL] (300 mL) [contains chloride 0.475 mEq/mL; 950 mOsm/L]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be infused without further dilution; maximum rate of I.V. infusion: 1 g/kg/hour (maximum: 60 g/hour).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pituitary function test (growth hormone)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F136618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of severe, uncompensated, metabolic alkalosis (pH &ge;7.55)",
"     <b>",
"      after",
"     </b>",
"     optimizing therapy with sodium and potassium supplements",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7905819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Food and Drug Administration (FDA) has identified several cases of fatal arginine overdose in children and has recommended that healthcare professionals always recheck dosing calculations prior to administration of arginine. Doses used in children should not exceed usual adult doses.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (with rapid I.V. infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Venous irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, cerebral edema, hematuria, hyperkalemia, hypersensitivity reaction, injection site reaction, skin burn/necrosis (due to extravasation), lethargy, loss of consciousness, perioral tingling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to arginine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Arginine infusion has been associated with acute electrolyte disturbances, including hyperkalemia, hyponatremia (following overdose), hypophosphatemia, and acidosis; risk is increased in patients with hepatic impairment, renal dysfunction, or diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe reactions, including anaphylaxis, have been reported; appropriate medical treatment should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation/extravasation: I.V. administration only. If extravasation occurs, local tissue damage may ensue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; use may lead to life-threatening hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Use with caution in patients with electrolyte imbalance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; use may lead to life-threatening hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction: Avoid use in myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; use may lead to life-threatening hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children. Several cases of fatal arginine overdose in children have been reported; symptoms of overdose may be delayed; healthcare professionals should always recheck dosing calculations prior to administration of arginine. Doses used in children should not exceed usual adult doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, the manufacturer does not recommend use of arginine during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F136601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amino acids are excreted in breast milk, the amount following arginine administration is not known.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F136602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product contains chloride.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (L-Arginine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (90): $7.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Arginine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $150.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2572943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acid-base status (arterial or capillary blood gases), serum electrolytes (sodium, potassium, chloride, bicarbonate, phosphorous), BUN, glucose, infusion site",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arginina (PL);",
"     </li>",
"     <li>",
"      Rocmaline (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates pituitary release of growth hormone and prolactin through origins in the hypothalamus; patients with impaired pituitary function have lower or no increase in plasma concentrations of growth hormone after administration of arginine. Arginine hydrochloride has been used for severe metabolic alkalosis due to its high chloride content. Arginine hydrochloride has been used investigationally to treat metabolic alkalosis. Arginine contains 475 mEq of hydrogen ions and 475 mEq of chloride ions/L. Arginine is metabolized by the liver to produce hydrogen ions. It may be used in patients with relative hepatic insufficiency because arginine combines with ammonia in the body to produce urea. Arginine is a precursor to nitric oxide and can produce vasodilation and inhibition of platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~33 L/kg following a 30 g I.V. dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 0.7-1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: ~2 hours; I.V.: 20-30 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bode-Boger SM, Boger RH, Galland A, et al, &ldquo;L-Arginine-induced Vasodilation in Healthy Humans: Pharmacokinetic-Pharmacodynamic Relationship,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1998, 46(5):489-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4980/abstract-text/9833603/pubmed\" id=\"9833603\" target=\"_blank\">",
"        9833603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bushinsky DA and Gennari FJ, &ldquo;Life-Threatening Hyperkalemia Induced by Arginine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1978, 89(5 Pt 1):632-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4980/abstract-text/717931/pubmed\" id=\"717931\" target=\"_blank\">",
"        717931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulman SP, Becker LC, Kass DA, &ldquo;L-Arginine Therapy in Acute Myocardial Infarction. The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial, &ldquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 295(1):58-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4980/abstract-text/16391217/pubmed\" id=\"16391217\" target=\"_blank\">",
"        16391217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8883 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4980=[""].join("\n");
var outline_f4_55_4980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136608\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136622\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136609\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136617\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136610\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136592\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136578\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136594\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136593\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136618\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7905819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136620\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136597\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136582\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298769\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136586\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136588\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136600\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136611\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136601\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136602\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322999\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2572943\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038532\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136581\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136596\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/56/35715?source=related_link\">",
"      Arginine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/3/23605?source=related_link\">",
"      Arginine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4981="Sacroiliitis grade 4 example 2";
var content_f4_55_4981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 4 example 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral grade 4 sacroiliitis with fusion of the sacroiliac joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4981=[""].join("\n");
var outline_f4_55_4981=null;
var title_f4_55_4982="Prenatal ultrasound normal renal Doppler";
var content_f4_55_4982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75147%7EOBGYN%2F73646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75147%7EOBGYN%2F73646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound normal renal Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound Doppler bilateral renal agenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4982=[""].join("\n");
var outline_f4_55_4982=null;
var title_f4_55_4983="Teniposide: Drug information";
var content_f4_55_4983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Teniposide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/17/36116?source=see_link\">",
"    see \"Teniposide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23686?source=see_link\">",
"    see \"Teniposide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vumon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vumon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Podophyllotoxin Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Down syndrome and leukemia may be more sensitive to the myelosuppressive effects; administer the first course at half the usual dose and adjust dose in subsequent cycles upward based on degree of toxicities (myelosuppression and mucositis) in the previous course(s).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL) consolidation treatment (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1, 4, 8, and 11 of alternating consolidation cycles (Linker, 1991)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F225371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23686?source=see_link\">",
"      see \"Teniposide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Down syndrome and leukemia may be more sensitive to the myelosuppressive effects; administer the first course at half the usual dose and adjust dose in subsequent cycles upward based on degree of toxicities (myelosuppression and mucositis) in the previous course(s).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL; combination chemotherapy):",
"     </b>",
"     I.V.: 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice weekly for 8-9 doses",
"     <b>",
"      or",
"     </b>",
"     250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 4-8 weeks",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1 and 2 of weeks 3, 13, and 23 (Lauer, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data is insufficient, but dose adjustments may be necessary in patient with significant renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F225354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data is insufficient, but dose adjustments may be necessary in patient with significant hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vumon&reg;: 10 mg/mL (5 mL) [contains benzyl alcohol, dehydrated ethanol 42.7%, polyoxyethylated castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.; must be administered slowly (over at least 30-60 minutes); do not administer by rapid I.V. injection. Administer through non-DEHP-containing administration sets. Incompatible with heparin; flush infusion line with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS before and after infusion. Precipitation may occur at any concentration; administer as soon as possible after preparation; inspect solution prior to administration. Observe patient continuously for at least the first 60 minutes of infusion, observe frequently thereafter. Stop infusion for signs of anaphylaxis (may require treatment with epinephrine, corticosteroids, antihistamines, pressors, or volume expanders); discontinue for clinically significant hypotension during infusion; if infusion is restarted after being withheld for hypotension, reinitiate at a slower infusion rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F225390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amikacin, aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, doxorubicin HCl, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol lactate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, ifosfamide, imipenem/cilastatin, leucovorin calcium, lorazepam, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, minocycline, mitomycin, mitoxantrone, morphine, nalbuphine, ondansetron, piperacillin, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sargramostim, sodium bicarbonate, streptozocin, thiotepa, ticarcillin/clavulanate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Idarubicin, heparin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory childhood acute lymphoblastic leukemia (ALL) in combination with other chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9645715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory acute lymphoblastic leukemia (ALL) in adults",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Teniposide may be confused with etoposide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Mucositis (76%), diarrhea (33%), nausea/vomiting (29%; mild to moderate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (95%), leukopenia (89%), anemia (88%), thrombocytopenia (85%), myelosuppression (75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (2%; associated with rapid [&lt;30 minutes] infusions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (9%; usually reversible), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (5%; includes bronchospasm, chills, dyspnea, fever, flushing, hyper-/hypotension, tachycardia, or urticaria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1%, postmarketing, and/or case reports: Arrhythmia, CNS depression, confusion, headache, hepatic dysfunction, intractable hypotension, metabolic abnormality, metabolic acidosis, neuropathy (severe), neurotoxicity, renal dysfunction, thrombophlebitis, tissue necrosis (upon extravasation), weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to teniposide, polyoxyethylated castor oil (Cremophor&reg; EL), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe myelosuppression resulting in infection or bleeding may occur;",
"     </b>",
"     may be dose-limiting; monitor blood counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: For I.V. use only; monitor infusion site; may cause local tissue necrosis or thrombophlebitis if extravasation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Hypersensitivity reactions, including anaphylaxis-like reactions, have been reported;",
"     </b>",
"     hypersensitivity reactions may include bronchospasm, dyspnea, hypertension, hypotension, tachycardia, flushing, chills, fever, or urticaria. Monitor closely during infusion (observe continuously for first 60 minutes, frequently thereafter). Stop infusion for signs of anaphylaxis; immediate treatment for anaphylactic reaction should be available during administration (may require treatment with epinephrine, corticosteroids, antihistamines, pressors, or volume expanders).  Patients experiencing prior hypersensitivity are at risk for recurrence; retreat only if the potential benefit outweighs the risk of hypersensitivity; premedication (with corticosteroids and antihistamines) is recommended for retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Hypotension may occur with rapid infusion; infuse slowly over at least 30-60 minutes; discontinue for clinically significant hypotension. If infusion is restarted after being withheld for hypotension, reinitiate at a slower infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity with high doses: Acute CNS depression, hypotension and metabolic acidosis have been reported; these events occurred in patients who received high-dose teniposide (investigation protocol) and were premedicated with antiemetics, which along with the alcohol content of teniposide, may have contributed to the depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution; may require dosage reduction in patients with significant impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution; may require dosage reduction in patients with significant impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vincristine: Neurotoxicity and severe neuropathy have been reported when teniposide is used in combination with vincristine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Down syndrome: Patients with Down syndrome and leukemia may be more sensitive to the myelosuppressive effects; reduced initial doses are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoalbuminemia: Since teniposide is highly bound to plasma proteins, carefully monitor patients with hypoalbuminemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Product contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydrated alcohol: Product contains about 43% alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polyoxyethylated castor oil: Contains polyoxyethylated castor oil (Cremophor&reg; EL), which is associated with hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Teniposide. Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Teniposide. Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Teniposide. Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Teniposide may enhance the neurotoxic effect of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): Teniposide may enhance the neurotoxic effect of VinCRIStine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease teniposide levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9645716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during teniposide treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9645718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if teniposide is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue teniposide or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vumon Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $376.55",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9645879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, platelet count, renal and hepatic function tests; blood pressure; monitor for hypersensitivity reaction (observe continuously for first 60 minutes of infusion, frequently thereafter)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      VM 26-Bristol (DE);",
"     </li>",
"     <li>",
"      Vumon (AR, AT, AU, BE, BG, BR, CH, CL, CN, CZ, ES, GR, HN, HU, IT, LU, MX, NL, NO, PL, PT, UY, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teniposide does not inhibit microtubular assembly; it has been shown to delay transit of cells through the S phase and arrest cells in late S or early G",
"     <sub>",
"      2",
"     </sub>",
"     phase, preventing cells from entering mitosis. Teniposide is a topoisomerase II inhibitor, and appears to cause DNA strand breaks by inhibition of strand-passing and DNA ligase action.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults: 8-44 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Children: 3-11 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; crosses blood-brain barrier to a limited extent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (44%, 4% to 12% as unchanged drug); feces (&le;10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Clark PI and Slevin ML, &ldquo;The Clinical Pharmacology of Etoposide and Teniposide,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1987, 12(4):223-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4983/abstract-text/3297462/pubmed\" id=\"3297462\" target=\"_blank\">",
"        3297462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2011, 57(2):191-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4983/abstract-text/21465637/pubmed\" id=\"21465637\" target=\"_blank\">",
"        21465637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauer SJ, Shuster JJ, Mahoney DH Jr, et al, &ldquo;A Comparison of Early Intensive Methotrexate/Mercaptopurine With Early Intensive Alternating Combination Chemotherapy for High-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Randomized Trial,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2001, 15(7):1038-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4983/abstract-text/11455971/pubmed\" id=\"11455971\" target=\"_blank\">",
"        11455971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linker CA, Levitt LJ, O'Donnell M, et al, &ldquo;Treatment of Adult Acute Lymphoblastic Leukemia With Intensive Cyclical Chemotherapy: A Follow-up Report,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1991 78(11):2814-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4983/abstract-text/1835410/pubmed\" id=\"1835410\" target=\"_blank\">",
"        1835410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muggia FM, &ldquo;Teniposide: Overview of Its Therapeutic Potential in Adult Cancers,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1994, 34(Suppl):127-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Dwyer PJ, Alonso MT, Leyland-Jones B, et al, &ldquo;Teniposide: A Review of 12 Years of Experience,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1984, 68(12):1455-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4983/abstract-text/6391663/pubmed\" id=\"6391663\" target=\"_blank\">",
"        6391663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rivera GK and Evans WE, &ldquo;Clinical Trials of Teniposide (VM-26) in Childhood Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1992, 19(2 Suppl 6):51-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salzer WL, Devidas M, Carroll WL, et al, &ldquo;Long-Term Results of the Pediatric Oncology Group Studies for Childhood Acute Lymphoblastic Leukemia 1984-200: A Report From the Children's Oncology Group,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2010, 24(2):355-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/55/4983/abstract-text/20016527/pubmed\" id=\"20016527\" target=\"_blank\">",
"        20016527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sonneveld P, &ldquo;Teniposide in Lymphomas and Leukemias,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1992, 19(2 Suppl 6):59-64.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9974 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-6DBE490E2D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4983=[""].join("\n");
var outline_f4_55_4983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709983\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225347\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225386\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225351\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225371\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225353\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225354\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225311\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225329\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225390\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225327\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645715\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225384\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225315\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225381\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225320\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225343\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225322\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645716\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225361\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645718\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323930\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645879\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225334\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225314\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225331\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9974|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/17/36116?source=related_link\">",
"      Teniposide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23686?source=related_link\">",
"      Teniposide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4984="Epidemiology of dengue virus infections";
var content_f4_55_4984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of dengue virus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4984/contributors\">",
"     Alan L Rothman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4984/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4984/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/55/4984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The viral etiology of dengue was established by the 1940s, and records of dengue-like illness date back more than 200 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/1\">",
"     1",
"    </a>",
"    ]. Major changes in the epidemiology of dengue virus infections began after World War II and have continued to date. Given current estimates of 50 to 100 million infections worldwide each year and over 2.5 billion individuals at risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/2\">",
"     2",
"    </a>",
"    ], the dengue viruses are now arguably the most important arthropod-borne viruses from a medical and public health perspective.",
"   </p>",
"   <p>",
"    The cardinal features of the dengue virus transmission cycle, the characteristics of the mosquito vectors, and the factors that have contributed and are contributing to dengue virus transmission in the major affected regions will be reviewed here. The pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of dengue virus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue viruses are members of the family Flaviviridae, genus flavivirus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The dengue virus complex comprises four antigenically related but distinct viruses, designated dengue virus serotypes 1 through 4. All dengue viruses are mosquito-borne human pathogens that exclusively cause acute infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRANSMISSION CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both epidemic and endemic transmission of dengue viruses are maintained through a human-mosquito-human cycle involving mosquitoes of the genus Aedes (Stegomyia) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/5\">",
"     5",
"    </a>",
"    ]. Transmission of dengue viruses between mosquitoes and nonhuman primates has been demonstrated to occur in Asia and Africa, but there is no evidence that such transmission is an important reservoir for transmission to humans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Susceptible humans become infected after being bitten by an infected female Aedes mosquito. Viremia in humans begins towards the end of a four to six-day incubation period and persists until fever abates, which is typically three to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. An uninfected Aedes mosquito may acquire the virus after feeding on the subject during this viremic period. The mosquito has an incubation period of 8 to 12 days before it is capable of transmitting the virus to susceptible people. Once infected, mosquitoes carry the virus for their lifespan and remain infective for humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MOSQUITO VECTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aedes (Stegomyia) aegypti mosquitoes, the principal vector for the transmission of dengue virus, have many characteristics that make them ideal for dissemination of the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. A. aegypti typically breed in or close to houses, laying eggs in both man-made and natural water containers. The typical flight distance is relatively short [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/10\">",
"     10",
"    </a>",
"    ]. A. aegypti are daytime feeders that prefer to bite humans and are frequently unnoticed. They are easily interrupted in their feeding and move on to another host, frequently taking multiple blood meals in a single breeding cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, an infected A. aegypti mosquito may transmit dengue virus to several individuals in a small area. For these reasons, family members who are at home during the day, typically women and young children, are thought to be at particularly high risk for infection.",
"   </p>",
"   <p>",
"    A. aegypti are widely distributed in tropical and subtropical areas from latitude 45&ordm; North to 35&ordm; South. Efforts to control urban yellow fever in the Americas, which is also principally transmitted by A. aegypti, had greatly restricted the distribution of the mosquitoes in the Western hemisphere as of 1970, but the mosquitoes have since reinfested nearly all of their former habitats [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A. albopictus mosquitoes are a competent vector for the transmission of dengue virus under both experimental and natural conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/5,12\">",
"     5,12",
"    </a>",
"    ] but are less likely to do so since they do not bite humans as frequently as A. aegypti and more often breed in outdoor water containers. A. albopictus also are more tolerant of the cold and have a wider geographic distribution than A. aegypti [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, they appear to be less efficient natural vectors for dengue virus; it has been rare to find either endemic transmission or large outbreaks in regions that have A. albopictus but not A. aegypti mosquitoes. Both A. albopictus and A. aegypti are also competent vectors for transmission of chikungunya virus, which has led to simultaneous outbreaks of both diseases in some areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other Aedes mosquitoes have been suspected of dengue virus transmission in isolated outbreaks in the Pacific islands [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/15\">",
"     15",
"    </a>",
"    ]. However, these species appear to play an insignificant role in the global transmission of dengue virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATTERNS OF TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue virus transmission follows two general (but not mutually exclusive) patterns, with different implications for disease risk in both the local population and travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epidemic dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemic dengue transmission occurs when the introduction of dengue virus into a region is an isolated event involving a single virus strain. If sufficiently large populations of susceptible hosts and mosquitoes are present, transmission of dengue is explosive, leading to a recognizable epidemic. The incidence of infection among susceptible individuals often reaches 25 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/16\">",
"     16",
"    </a>",
"    ], and can be considerably higher. Herd immunity, changes in weather, and mosquito control efforts can all contribute to the termination of the epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of dengue viruses prior to World War II almost exclusively followed this pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/17\">",
"     17",
"    </a>",
"    ]. Seaports frequently were the point of initial introduction of dengue viruses, and these port cities then acted as distribution points to nearby inland areas.",
"   </p>",
"   <p>",
"    Epidemic activity is currently the predominant pattern of dengue virus transmission in smaller island nations, certain areas of South America and Africa, and in the areas of Asia where dengue virus transmission has recently reemerged. The incidence of dengue virus infections in these locations varies considerably from year to year. Intervals of several years or more usually pass between epidemics, allowing the number of susceptible individuals to accumulate so that the next epidemic can be perpetuated.",
"   </p>",
"   <p>",
"    The implications of a predominantly epidemic pattern of dengue transmission are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for acquisition of dengue virus for travelers is high during an epidemic but low at other times. However, outbreaks may be relatively difficult to predict.",
"     </li>",
"     <li>",
"      Both adults and children are affected in the local population.",
"     </li>",
"     <li>",
"      The frequency of dengue hemorrhagic fever (DHF) has usually been low during epidemics, with some significant exceptions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/18\">",
"       18",
"      </a>",
"      ]. The viral serotype and strain and the interval since the previous epidemic seem to influence the risk for this manifestation of infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"       \"Pathogenesis of dengue virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hyperendemic dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Hyperendemic\" transmission refers to the continuous circulation of multiple dengue virus serotypes in the same area. This requires the year-round presence of competent vector mosquitoes and either a large population base or steady movement of individuals into the area to maintain a pool of susceptible individuals. Hyperendemic circulation involves the occurrence of multiple epidemics in a smaller geographic scale (eg, village or school) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seasonal variation in virus transmission is common. The incidence of infection also varies from year to year, with increased dengue transmission at intervals of three to four years, but this variation is not as dramatic as in areas where transmission predominantly follows the epidemic pattern. A recent mathematical analysis of data from Thailand suggested that these surges in dengue transmission originate in waves from major urban centers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Areas with hyperendemic dengue virus transmission contribute the vast majority of cases of dengue virus infection globally. In some regions, 5 and 10 percent of the susceptible population experiences dengue virus infection annually [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Urban areas are particularly affected.",
"   </p>",
"   <p>",
"    The implications of hyperendemic transmission of dengue virus are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall risk for acquisition of dengue virus is higher for travelers than in areas that experience only epidemic transmission, but the seasonal variation in risk is somewhat predictable.",
"     </li>",
"     <li>",
"      The prevalence of antibody against dengue virus rises with age for the local population, and most adults are immune to infection.",
"     </li>",
"     <li>",
"      While children are more likely than adults to experience mild disease, hyperendemicity appears to be a major factor contributing to the occurrence of DHF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"       \"Pathogenesis of dengue virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FACTORS INFLUENCING TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the transmission cycle for dengue viruses is dependent upon the interaction between infective mosquitoes and susceptible humans and between susceptible mosquitoes and viremic humans. Dengue virus transmission is enhanced by the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increased vector density",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many tropical countries, seasonal increases in rainfall contribute to an increased density of mosquitoes. One factor that can be modified is the presence of open water storage containers in or near the home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Shorter incubation period in the mosquito",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of the incubation time in the mosquito, known as the extrinsic incubation period, is inversely associated with the ambient temperature. Warmer temperatures therefore increase the length of time that a mosquito remains infective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased movement of mosquito vectors and viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air, land, and water transportation of mosquitoes or viremic humans facilitate the dissemination of dengue viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Increased density of susceptible human hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crowded conditions probably increase the potential for virus transmission. However, as the prevalence of prior infection increases, the fraction of the population that remains susceptible is reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Increased duration and magnitude of viremia in humans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuated virus strains produced in the laboratory have been shown to produce low titers of virus in the blood, which are then not efficiently transmitted to mosquitoes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It is unclear whether natural strains of dengue virus can differ in the viremia titers they produce [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER ROUTES OF TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high titers of infectious dengue virus found in blood and tissues during acute infection, it is not surprising that the potential exists for virus transmission by routes other than mosquito vectors:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nosocomial transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least four well-documented cases of transmission of dengue virus in the health care setting via needlestick and one case of transmission by non-percutaneous exposure have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/27\">",
"     27",
"    </a>",
"    ]. Some blood donors, although asymptomatic, have levels of viremia sufficient to transmit infection to recipients of their blood components [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/28\">",
"     28",
"    </a>",
"    ]. Cases of nosocomial transmission in dengue-endemic regions (also likely to encompass the majority of exposures) would usually be overlooked due to the inability to distinguish nosocomial transmission from mosquito transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vertical transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical transmission of dengue has been reported in a few small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/29\">",
"     29",
"    </a>",
"    ]; based on these cases and the known pattern of viremia, this possibility should be considered in cases where illness in the mother occurs within the 10 days before delivery (including onset on the day of delivery). Illness presented in these newborns up to 11 days (median 4 days) after birth. Although data are limited, pregnancy does not appear to increase the incidence or severity of dengue [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/30\">",
"     30",
"    </a>",
"    ]. In a prospective study conducted in Kuala Lumpur of 2958 parturients, 2531 paired maternal-umbilical cord blood samples were tested for dengue-specific IgM to determine the prevalence of infection and the vertical transmission rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/31\">",
"     31",
"    </a>",
"    ]. Sixty-three women (2.5 percent) had a positive IgM serology. Only one (1.6 percent, 95% CI 0-9.5%) of the paired umbilical cord samples was seropositive for dengue. None of the maternal and fetal blood samples had evidence of viral RNA by PCR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FACTORS CONTRIBUTING TO THE REEMERGENCE OF DENGUE AND DENGUE HEMORRHAGIC FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The worldwide incidence of dengue and DHF has been increasing in the past several decades, and the geographic distribution of these diseases has expanded. The emergence of DHF as a public health problem has largely been a result of human behaviors including [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Population growth",
"     </li>",
"     <li>",
"      Poorly planned urbanization, associated with overcrowding, poor water distribution, and poor sanitation",
"     </li>",
"     <li>",
"      Changing lifestyles, such as increased reliance on plastic containers and tires; standing water can easily collect in these",
"     </li>",
"     <li>",
"      Modern transportation, with increased movement of viruses, mosquitoes, and susceptible humans",
"     </li>",
"     <li>",
"      Lack of effective mosquito control",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential effects of global climate change are a major source of concern for the future. Increased dengue virus transmission has been associated with El",
"    <span class=\"nowrap\">",
"     Nino/Southern",
"    </span>",
"    Oscillation events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Mathematical models predict that increased global temperatures will further expand the range of A. aegypti and dengue virus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISTRIBUTION OF A. AEGYPTI AND REPORTED DENGUE ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently A. aegypti and dengue viruses are endemic in every continent except Europe and Antarctica (",
"    <a class=\"graphic graphic_figure graphicRef60722 \" href=\"UTD.htm?40/6/41058\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/4,36\">",
"     4,36",
"    </a>",
"    ], although epidemic DHF occurs predominantly in Asia and the Americas. The risk for exposure to A. aegypti is often higher in urban areas. Many tourist facilities present a lower risk than local residential areas because of air conditioning, groundskeeping, elevation, or combinations of these factors.",
"   </p>",
"   <p>",
"    The number of cases of dengue fever (DF) and DHF reported globally has varied considerably from year to year, although the overall trend is one of increasing incidence. Global epidemics of disease have occurred at intervals of several years, most recently from 2001 to 2002. Several regions have reported increased dengue disease activity from 2007 through 2009 (See below).",
"   </p>",
"   <p>",
"    The reported dengue activity in specific regions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/37-40\">",
"     37-40",
"    </a>",
"    ] is described further below. Most available information is gathered through passive surveillance activities and must be interpreted cautiously in light of underreporting of cases and lack of laboratory confirmation (",
"    <a class=\"graphic graphic_table graphicRef70287 \" href=\"UTD.htm?5/47/5886\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Southeast Asia and Western Pacific regions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Southeast Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti are present throughout the region, extending to southern China and the south of the island of Taiwan, and all countries in the region are affected by dengue virus infections. Hyperendemic transmission of all four dengue serotypes, with cases of DHF, has been present in Thailand, Vietnam, and Indonesia for over 40 years. Epidemic dengue reemerged in China during the 1980s and the 1990s after an absence of several decades, and was associated with the first occurrence of DHF in that country [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/41\">",
"     41",
"    </a>",
"    ]. Nepal, the last country in the region to be affected, had the first cases detected in 2004. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12568?source=see_link\">",
"     \"Diseases potentially acquired by travel to Southeast Asia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13319?source=see_link\">",
"     \"Diseases potentially acquired by travel to East Asia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dengue virus transmission occurs year-round, but typically reaches a seasonal peak which varies in timing from one country to another (for example, between June and November in Thailand, but between January and February in Indonesia). More than 200,000 cases of DHF were reported from the region in each year from 2007 through 2009; Indonesia accounted for the majority of cases in each of these years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     South Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti are present in most of the region. Hyperendemic transmission of all four dengue serotypes is present in Malaysia and the Philippines. Other islands experience frequent dengue outbreaks; high incidence rates were reported from 14 island nations for 2009, including American Samoa, Cook Islands, French Polynesia, New Caledonia, and Tonga [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Western Pacific islands",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti are present in most of the region. Hyperendemic transmission of all four dengue serotypes is present in Malaysia and the Philippines. Other islands experience frequent dengue outbreaks; in the first half of 2009, over 1000 cases have been reported from French Polynesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9113?source=see_link\">",
"     \"Potential health hazards in travelers to Australia, New Zealand, and the southwestern Pacific (Oceania)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Australia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti are present in the northeastern corner of Australia. Dengue viruses are not endemic to the continent, but periodic introduction of dengue viruses from neighboring islands led to epidemics in urban areas of north Queensland during the 1990s and 2000s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9113?source=see_link\">",
"     \"Potential health hazards in travelers to Australia, New Zealand, and the southwestern Pacific (Oceania)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     African and Eastern Mediterranean regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti are present in much of sub-Saharan Africa and the Middle East. Data are scant on dengue virus transmission. However, documented infections in visitors to the area indicate that there is ongoing dengue virus transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Several outbreaks were reported from central Africa, east Africa and the Middle East during the 1990s and 2000s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/14,36\">",
"     14,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Region of the Americas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     North America",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti are present in most areas of Mexico and in the southeastern United States. A. albopictus is also present in these areas, but its range extends further north, nearly to the Great Lakes. Hyperendemic transmission of all four dengue virus serotypes is present throughout the range of A. aegypti in Mexico. Dengue virus transmission is seasonal, with peak activity in late summer and fall. In 2011, over 67,000 cases of dengue infection were reported from Mexico, including 4000 cases of severe dengue and 36 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most dengue virus infections identified in the continental United States and all cases identified in Canada were acquired during travel abroad or to Puerto Rico or the United States Virgin Islands [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Limited transmission of dengue virus (3 to 30 cases) within southern Texas was documented in 1980, 1986, 1995, 1997, and 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/51\">",
"     51",
"    </a>",
"    ], and an outbreak involving over 120 cases of locally acquired dengue infection occurred in Hawaii in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/52\">",
"     52",
"    </a>",
"    ]. However, in 2007, the CDC reported a case of DHF in a resident native to Texas who lived in a bordering area with Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/53\">",
"     53",
"    </a>",
"    ]. This prompted a serosurvey of 346 households in the immediate neighborhood, which demonstrated that 38 percent of the residents had IgG antibodies to dengue. In 2010, dengue fever was also reported in 28 residents of Key West, Florida who had not traveled abroad [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/54\">",
"     54",
"    </a>",
"    ]. A subsequent serosurvey of 240 participants living in Key West found that 5 percent had evidence of recent dengue infection. Local transmission of dengue virus has been detected in south Florida, but still appears to be very limited in scope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Central America",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti and hyperendemic transmission of all four dengue virus serotypes are present throughout the region. The region experienced a major outbreak in 2010; Honduras and Costa Rica reported among the highest numbers of cases of dengue (67,000 and 31,000, respectively) and incidence rates (1016 and 979 cases per 100,000 population) that year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/40\">",
"     40",
"    </a>",
"    ]. However, all of these countries have had one or more years of heavy dengue activity during the past five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Caribbean",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti is present throughout the region. Hyperendemic circulation of dengue virus serotypes 1, 2, and 4 has been present on the larger islands (other than Cuba) for several decades and dengue virus serotype 3 has been present since 1998. In Puerto Rico, peak dengue virus transmission usually occurs between October and December; over 21,000 cases of dengue virus infection were reported there in 2010. The Dominican Republic (11,000 cases), French Guiana (4000 cases), Guadeloupe (41,000 cases), Martinique (37,000 cases), and St. Martin (2400 cases) all reported major outbreaks in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/40\">",
"     40",
"    </a>",
"    ]. Other islands have experienced periodic dengue epidemics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     South America",
"    </span>",
"    &nbsp;&mdash;&nbsp;A. aegypti is present in every South American country except Chile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/36\">",
"     36",
"    </a>",
"    ]. Hyperendemic circulation of all four dengue virus serotypes has been present in the north of the continent since the reintroduction of dengue virus serotype 3 was detected in Brazil and Venezuela during 2000. Brazil, Venezuela, and Colombia have reported the largest number of dengue cases. Low-level, year-round transmission has been observed, but most cases follow an epidemic pattern; in Brazil, peak dengue transmission occurs between February and May [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brazil experienced a major outbreak in 2010, concentrated in the state of Rio de Janeiro, and with over 1,000,000 cases nationwide, including over 16,000 cases of severe dengue [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4984/abstract/40\">",
"     40",
"    </a>",
"    ]. Colombia (150,000 cases) and Venezuela (120,000 cases) also reported major dengue outbreaks in 2010. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H485691\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dengue viruses are members of the family Flaviviridae, genus flavivirus. The dengue virus complex comprises four antigenically related but distinct viruses, which are mosquito-borne human pathogens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Susceptible humans become infected after being bitten by an infected female Aedes mosquito. Viremia in humans begins towards the end of a four- to six-day incubation period and persists until fever abates. An uninfected Aedes mosquito may acquire the virus after feeding on an infected individual during this viremic period. Once infected, mosquitoes carry the virus for their lifespan and remain infective for humans. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aedes aegypti mosquitoes are daytime feeders that prefer to bite humans and are frequently unnoticed. They are easily interrupted in their feeding and move on to another host, frequently taking multiple blood meals in a single breeding cycle. Thus, an infected A. aegypti mosquito may transmit dengue virus to several individuals within a small geographic area. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mosquito vectors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemic dengue transmission occurs when the introduction of dengue virus into a region is an isolated event involving a single virus strain. If sufficiently large populations of susceptible hosts and mosquitoes are present, transmission of dengue is explosive, leading to a recognizable epidemic. Herd immunity, changes in weather, and mosquito control efforts can all contribute to the termination of the epidemic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemic dengue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      \"Hyperendemic\" transmission refers to the continuous circulation of multiple dengue virus serotypes in the same area. This requires the year-round presence of competent vector mosquitoes and an ongoing presence of susceptible individuals. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hyperendemic dengue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dengue virus transmission is enhanced by multiple factors, including higher vector density, greater movement of mosquito vectors, and increased density of susceptible humans. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Factors influencing transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aedes aegypti and dengue viruses are endemic in every continent except Europe and Antarctica, although epidemic dengue hemorrhagic fever occurs predominantly in Asia and the Americas. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Distribution of A. Aegypti and reported dengue activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rush AB. An account of the bilious remitting fever, as it appeared in Philadelphia in the summer and autumn of the year 1780. In: Medical Inquiries and Observations, Richard &amp; Hall, Philadelphia  p.104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/2\">",
"      Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/3\">",
"      Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990; 3:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/4\">",
"      Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005; 353:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/5\">",
"      Kuno G. Review of the factors modulating dengue transmission. Epidemiol Rev 1995; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/6\">",
"      Wang E, Ni H, Xu R, et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol 2000; 74:3227.",
"     </a>",
"    </li>",
"    <li>",
"     Gubler DJ. Epidemic dengue and dengue hemorrhagic fever: a global public health problem in the 21st century. In: Emerging Infections I, Scheld WM, Armstrong D, Hughes JM (Eds), ASM Press, Washington, DC 1998. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/8\">",
"      Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/9\">",
"      Halstead SB. Selective primary health care: strategies for control of disease in the developing world. XI. Dengue. Rev Infect Dis 1984; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/10\">",
"      Harrington LC, Scott TW, Lerdthusnee K, et al. Dispersal of the dengue vector Aedes aegypti within and between rural communities. Am J Trop Med Hyg 2005; 72:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/11\">",
"      Scott TW, Amerasinghe PH, Morrison AC, et al. Longitudinal studies of Aedes aegypti (Diptera: Culicidae) in Thailand and Puerto Rico: blood feeding frequency. J Med Entomol 2000; 37:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/12\">",
"      Gratz NG. Critical review of the vector status of Aedes albopictus. Med Vet Entomol 2004; 18:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/13\">",
"      Centers for Disease Control (CDC). Update: Aedes albopictus infestation--United States, Mexico. MMWR Morb Mortal Wkly Rep 1989; 38:440, 445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/14\">",
"      Caron M, Paupy C, Grard G, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 2012; 55:e45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/15\">",
"      Savage HM, Fritz CL, Rutstein D, et al. Epidemic of dengue-4 virus in Yap State, Federated States of Micronesia, and implication of Aedes hensilli as an epidemic vector. Am J Trop Med Hyg 1998; 58:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/16\">",
"      McBride WJ, Mullner H, LaBrooy JT, Wronski I. The 1993 dengue 2 epidemic in North Queensland: a serosurvey and comparison of hemagglutination inhibition with an ELISA. Am J Trop Med Hyg 1998; 59:457.",
"     </a>",
"    </li>",
"    <li>",
"     Gubler DJ. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem. In: Dengue and Dengue Hemorrhagic Fever, Gubler DJ, Kuno G (Eds), CAB International, Wallingford 1997. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/18\">",
"      Kouri GP, Guzm&aacute;n MG, Bravo JR, Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989; 67:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/19\">",
"      Endy TP, Nisalak A, Chunsuttiwat S, et al. Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/20\">",
"      Cummings DA, Irizarry RA, Huang NE, et al. Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand. Nature 2004; 427:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/21\">",
"      Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/22\">",
"      Porter KR, Beckett CG, Kosasih H, et al. Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia. Am J Trop Med Hyg 2005; 72:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/23\">",
"      Endy TP, Chunsuttiwat S, Nisalak A, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/24\">",
"      Bhamarapravati N, Yoksan S, Chayaniyayothin T, et al. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987; 65:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/25\">",
"      Schoepp RJ, Beaty BJ, Eckels KH. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation. Am J Trop Med Hyg 1991; 45:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/26\">",
"      Gubler DJ, Suharyono W, Lubis I, et al. Epidemic dengue 3 in central Java, associated with low viremia in man. Am J Trop Med Hyg 1981; 30:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/27\">",
"      Chen LH, Wilson ME. Transmission of dengue virus without a mosquito vector: nosocomial mucocutaneous transmission and other routes of transmission. Clin Infect Dis 2004; 39:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/28\">",
"      Stramer SL, Linnen JM, Carrick JM, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/29\">",
"      Sirinavin S, Nuntnarumit P, Supapannachart S, et al. Vertical dengue infection: case reports and review. Pediatr Infect Dis J 2004; 23:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/30\">",
"      Carroll ID, Toovey S, Van Gompel A. Dengue fever and pregnancy - a review and comment. Travel Med Infect Dis 2007; 5:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/31\">",
"      Tan PC, Rajasingam G, Devi S, Omar SZ. Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome. Obstet Gynecol 2008; 111:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/32\">",
"      Hales S, Weinstein P, Woodward A. Dengue fever epidemics in the South Pacific: driven by El Ni&ntilde;o Southern Oscillation? Lancet 1996; 348:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/33\">",
"      Dengue. Wkly Epidemiol Rec 1998; 73:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/34\">",
"      Jetten TH, Focks DA. Potential changes in the distribution of dengue transmission under climate warming. Am J Trop Med Hyg 1997; 57:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/35\">",
"      Hales S, de Wet N, Maindonald J, Woodward A. Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet 2002; 360:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/36\">",
"      Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 1997; 50:161.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Report on Global Surveillance of Epidemic-Prone Infectious Diseases. www.who.int/csr/resources/publications/dengue/CSR_ISR_2000_1/en (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     DengueNet www.who.int/denguenet (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     Situation of Dengue/DHF in SEA www.searo.who.int/en/section10/section332.htm (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     PanAmerican Health Organization. Dengue. file://new.paho.org/hq/index.php?option=com_content&amp;task=view&amp;id=264&amp;Itemid=363&amp;lang=en (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/41\">",
"      Qiu FX, Gubler DJ, Liu JC, Chen QQ. Dengue in China: a clinical review. Bull World Health Organ 1993; 71:349.",
"     </a>",
"    </li>",
"    <li>",
"     Dengue in the Western Pacific Region file://www.wpro.who.int/entity/emerging_diseases/Dengue/en/index.html (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/43\">",
"      Dengue in the WHO Western Pacific Region. Wkly Epidemiol Rec 1998; 73:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/44\">",
"      Mackenzie JS, Broom AK, Hall RA, et al. Arboviruses in the Australian region, 1990 to 1998. Commun Dis Intell 1998; 22:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/45\">",
"      Eisenhut M, Schwarz TF, Hegenscheid B. Seroprevalence of dengue, chikungunya and Sindbis virus infections in German aid workers. Infection 1999; 27:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/46\">",
"      Sharp TW, Wallace MR, Hayes CG, et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg 1995; 53:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Imported dengue--United States, 1997 and 1998. MMWR Morb Mortal Wkly Rep 2000; 49:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/48\">",
"      Rigau-P&eacute;rez JG, Gubler DJ, Vorndam AV, Clark GG. Dengue surveillance--United States, 1986-1992. MMWR CDC Surveill Summ 1994; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Travel-associated dengue infections--United States, 2001-2004. MMWR Morb Mortal Wkly Rep 2005; 54:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: school reporting of a dengue outbreak - st. Croix, u.s. Virgin islands, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). Imported dengue--United States, 1996. MMWR Morb Mortal Wkly Rep 1998; 47:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/52\">",
"      Effler PV, Pang L, Kitsutani P, et al. Dengue fever, Hawaii, 2001-2002. Emerg Infect Dis 2005; 11:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Dengue hemorrhagic fever--U.S.-Mexico border, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/54\">",
"      Centers for Disease Control and Prevention (CDC). Locally acquired Dengue--Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep 2010; 59:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4984/abstract/55\">",
"      Siqueira JB Jr, Martelli CM, Coelho GE, et al. Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg Infect Dis 2005; 11:48.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3028 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4984=[""].join("\n");
var outline_f4_55_4984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H485691\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRANSMISSION CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MOSQUITO VECTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATTERNS OF TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epidemic dengue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hyperendemic dengue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FACTORS INFLUENCING TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increased vector density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Shorter incubation period in the mosquito",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased movement of mosquito vectors and viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Increased density of susceptible human hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Increased duration and magnitude of viremia in humans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER ROUTES OF TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nosocomial transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vertical transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FACTORS CONTRIBUTING TO THE REEMERGENCE OF DENGUE AND DENGUE HEMORRHAGIC FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISTRIBUTION OF A. AEGYPTI AND REPORTED DENGUE ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Southeast Asia and Western Pacific regions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Southeast Asia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - South Asia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Western Pacific islands",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Australia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      African and Eastern Mediterranean regions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Region of the Americas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - North America",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Central America",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Caribbean",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - South America",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H485691\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3028\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3028|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/6/41058\" title=\"figure 1\">",
"      Map of epidemic dengue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3028|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/47/5886\" title=\"table 1\">",
"      Distribution of dengue virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13319?source=related_link\">",
"      Diseases potentially acquired by travel to East Asia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12568?source=related_link\">",
"      Diseases potentially acquired by travel to Southeast Asia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=related_link\">",
"      Pathogenesis of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9113?source=related_link\">",
"      Potential health hazards in travelers to Australia, New Zealand, and the southwestern Pacific (Oceania)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=related_link\">",
"      Prevention and treatment of dengue virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4985="Clinical trials of immunosuppressive therapy in proliferative lupus nephritis";
var content_f4_55_4985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of immunosuppressive therapy in proliferative lupus nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4985/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/55/4985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2195479\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of lupus nephritis (LN) varies with the type of disease that is present. Immunosuppressive therapy is indicated in patients with diffuse and severe focal proliferative LN.",
"   </p>",
"   <p>",
"    Clinical trials of immunosuppressive therapy of proliferative LN are reviewed here. Prognostic factors and recommendations for the treatment of proliferative LN are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12345?source=see_link\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy refers to the initial therapeutic regimen given in an attempt to produce remission of active disease. This is followed in almost all patients by maintenance therapy, usually with less toxic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cyclophosphamide versus other agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     NIH trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial at the NIH compared three regimens in 65 patients with a mean serum creatinine of approximately 1.6 to 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (142 to 177",
"    <span class=\"nowrap\">",
"     micromol/L):",
"    </span>",
"    six monthly pulses of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ; a similar regimen followed by maintenance pulses every three months for another 24 months; and six monthly pulses of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/m2)",
"    </span>",
"    without cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/1\">",
"     1",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was also given, beginning at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and then tapering over a period of months to alternate-day maintenance therapy for control of extrarenal symptoms (minimum dose 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day).",
"   </p>",
"   <p>",
"    At follow-up of three years, the following differences were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of a doubling of the serum creatinine was significantly lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      groups (25 versus 48 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      alone).",
"     </li>",
"     <li>",
"      The likelihood of relapse was significantly higher in the short-course (six monthly pulses) as opposed to the long-course",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      regimen (",
"      <a class=\"graphic graphic_figure graphicRef78482 \" href=\"UTD.htm?13/48/14093\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although the group treated with only six monthly pulses did not do as well as those treated with more prolonged therapy, patients with relatively mild disease (serum creatinine &le;1.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&le;115",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      protein excretion &le;1.0",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      had a favorable prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One criticism of this trial is that the pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    course was too short.",
"   </p>",
"   <p>",
"    A subsequent NIH trial in 82 patients with mostly diffuse proliferative lupus nephritis and a mean baseline serum creatinine of approximately 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    compared three regimens: one year of monthly pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/m2);",
"    </span>",
"    pulse intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    monthly for six months and then quarterly for at least two years); and combination therapy methylprednisolone plus cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/2\">",
"     2",
"    </a>",
"    ]. All patients also received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as in the earlier NIH study described above.",
"   </p>",
"   <p>",
"    At a median follow-up of five years, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission (&lt;10 red blood cells per high power field, no cellular casts, and proteinuria &lt;1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      occurred in 85, 62 and 29 percent of the 65 non-censored patients treated with combination therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      alone, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      alone, respectively. Renal remission considering censored patients as failures occurred in 61, 48, and 26 percent, respectively.",
"     </li>",
"     <li>",
"      Relapse occurred in 0, 7, and 36 percent of the patients treated with combination therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      alone, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      alone, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      therapy was associated with a higher incidence of adverse events. Osteonecrosis occurred almost as frequently as with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      alone, infections and amenorrhea were more frequent, and the three deaths were in the cyclophosphamide groups. (",
"      <a class=\"graphic graphic_table graphicRef62047 \" href=\"UTD.htm?31/27/32187\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcomes of this cohort were further evaluated at a median follow-up of 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/3\">",
"     3",
"    </a>",
"    ]. Treatment failure (defined as requiring supplemental immunosuppression, doubling of the serum creatinine, or death) was significantly less likely with combination pulse therapy or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    alone than with pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    alone. As an example, doubling of the serum creatinine occurred significantly less often with combination therapy (1 of 20 patients) than with cyclophosphamide alone (13 of 21) or methylprednisolone alone (15 of 24).",
"   </p>",
"   <p>",
"    In terms of adverse effects, avascular necrosis occurred with similar frequency in all three groups (30 to 36 percent), but osteoporosis was less frequent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    group (13 percent) compared to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    alone (23 percent) or combination groups (21 percent). The mortality rate was higher in the patients treated with cyclophosphamide compared to those treated with methylprednisolone alone (18 versus 4 percent).",
"   </p>",
"   <p>",
"    Thus, the reported benefit in terms of renal survival must be weighed against the higher mortality rate. In addition, the reported benefit of combination therapy may not be clinically applicable to all patients with diffuse proliferative lupus nephritis given study design flaws, and the relatively well preserved kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dutch Working Party on SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial by the Dutch Working Party on Systemic Lupus Erythematosus included 87 patients with mostly class diffuse proliferative lupus nephritis who had a mean serum creatinine 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (112",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and mean protein excretion of 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/5\">",
"     5",
"    </a>",
"    ]. The patients were assigned to pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (750",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    monthly for six months, then every three months for seven doses) or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two years) plus pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1000 mg intravenously for three days, repeated at two and six weeks); all patients were treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . After the initial two years, all patients were treated with azathioprine maintenance therapy (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone for two more years, then lower doses for an additional year.",
"   </p>",
"   <p>",
"    During the initial two years of therapy, there were no differences between the two groups in the rate of complete and partial remissions (90 percent). However, after a median follow-up of 5.7 years, the rate of relapse was significantly lower in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    group (4 versus 27 percent). Cyclophosphamide therapy was also associated with nonsignificant doubling of the serum creatinine (4 versus 16 percent) and deaths or end-stage renal disease (4 versus 11 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Duration of cyclophosphamide therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of initial pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy is not known. In the NIH trial cited above, the best long-term renal outcomes were attained with the following regimen: pulse intravenous cyclophosphamide (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    monthly for six months and then quarterly for at least two years) combined with pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    on three consecutive days the first month and then a single infusion monthly for at least one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, long courses of therapy are associated with increased toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an attempt to reduce toxicity by limiting exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , two other trials (the Lupus Nephritis Collaborative Study and the Euro-Lupus Nephritis Trial) have evaluated shorter courses cyclophosphamide regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lupus Nephritis Collaborative Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lupus Nephritis Collaborative Study attempted to control disease activity with a much shorter, and therefore less toxic, course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study of 86 patients (40 percent with diffuse proliferative lupus, mean serum creatinine at baseline 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [188",
"    <span class=\"nowrap\">",
"     &micro;mol/L]),",
"    </span>",
"    oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was given for only",
"    <strong>",
"     eight weeks",
"    </strong>",
"    . Patients also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 60 to 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four weeks, followed by tapering to 20 to 25 mg every other day over a period of 32 weeks. Exacerbations were treated with increasing doses of prednisone. Sixty-three of 86 enrolled patients completed at least 48 weeks of follow-up. At a mean follow-up of three years, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-one percent developed renal failure",
"     </li>",
"     <li>",
"      The likelihood of renal failure was related to kidney function at baseline and initial response. Seven and 29 percent of patients with initial serum creatinine &le;1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or above 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (106",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      developed renal failure, respectively. Forty and 16 percent, respectively, had at least a 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (254",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      elevation in serum creatinine. Failure to respond to treatment within 48 weeks was associated with a higher risk of developing renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter findings are similar to those in a preliminary report of one of the NIH studies mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. These two studies suggest that patients with diffuse proliferative lupus nephritis who have mild clinical disease might do well with relatively short-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy. However, as previously mentioned, a potentially important limitation of these reports is that the duration of follow-up was far too short. The initial NIH trials, for example, showed that patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone (the group with the worst outcome) did not progress to renal failure until at least five years after the institution of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Euro-Lupus Nephritis trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;To better assess the long-term effect of low-dose short-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , 90 patients with proliferative lupus nephritis (two-thirds with diffuse proliferative histology) were randomly assigned either to six pulses of fixed low dose (500 mg) intravenous cyclophosphamide given every two weeks (cumulative dose of 3.0 g) or to six monthly doses of intravenous cyclophosphamide and then two quarterly pulses (0.5",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    initially, with subsequent doses increased or decreased based upon white blood cell count nadir) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/7\">",
"     7",
"    </a>",
"    ].All patients also received an initial pulse of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (3 daily pulses of 750 mg); this was followed by oral glucocorticoids (initial dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    for four weeks), which was subsequently tapered to low dose maintenance therapy. Two weeks after the last cyclophosphamide infusion in both arms,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was started and continued to at least month 30.",
"   </p>",
"   <p>",
"    At follow-up at a median of 41 months, there was no significant difference between the two arms in the rates of treatment failure (16 versus 20 percent in the high dose groups), renal remissions (71 versus 54 percent), and renal flares (27 versus 29 percent). The similarity in outcomes persisted at 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/11\">",
"     11",
"    </a>",
"    ]. On multivariate analysis, a good early response to therapy was predictive of better long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in this group of Europeans, a low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    induction regimen was as effective as a high dose regimen. However, the generalizability of these results is unclear, given that the study only enrolled Europeans without significant renal dysfunction (mean baseline serum creatinine 1.15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [102",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    Another strategy to reduce toxicity associated with long duration of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    consists of induction with short-term cyclophosphamide followed by maintenance therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the best comparative trial, 59 patients with lupus nephritis (12 with focal proliferative, 46 with diffuse proliferative, and 1 with membranous lupus) received induction therapy with four to a maximum of seven consecutive monthly doses of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m2)",
"    </span>",
"    plus glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/13\">",
"     13",
"    </a>",
"    ]. The mean dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or a glucocorticoid equivalent) during induction was 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months followed by 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three additional months.",
"   </p>",
"   <p>",
"    Over 80 percent of patients entered into remission during the induction phase. These patients were randomly assigned to one of the following therapies for two to three years:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    (500 to 3000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    every three months). Glucocorticoids were continued during maintenance therapy at doses ranging from 0.04 to 0.20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    The following results were observed at six years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      was associated with significantly lower incidence of chronic kidney disease, which was defined as a sustained increase in the serum creatinine to at least twice the lowest baseline achieved during induction therapy (5 and 5 versus 15 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The relapse rate (defined as doubling of the urine protein-to-creatinine ratio or by an increase in the serum creatinine) was higher among patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Adverse effects (including severe infections), and mortality versus that observed with long-term intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . Although concerns include the high rate of infections and progressive renal disease attributed to cyclophosphamide, the use of six months of monthly intravenous cyclophosphamide followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for maintenance therapy should, at minimum, be considered an excellent therapeutic option as the induction plus maintenance regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) may be an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as initial therapy, particularly among patients who refuse or cannot tolerate cyclophosphamide. Several prospective trials have addressed this issue with mycophenolate being at least noninferior to cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/15-21\">",
"     15-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial trials were small and may have been underpowered to detect a difference between the treatment regiments. A 2007 meta-analysis evaluated outcomes of 268 patients from four randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/15\">",
"     15",
"    </a>",
"    ]. Compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    resulted in a significantly lower risk of failure of inducing remission (relative risk [RR] 0.70, 95% CI 0.54-0.90).",
"   </p>",
"   <p>",
"    Significant limitations in this analysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies of limited quality were included.",
"     </li>",
"     <li>",
"      The findings may not be generalizable, since the patients had relatively preserved renal function and a widely varying risk of remission.",
"     </li>",
"     <li>",
"      The initial duration of follow-up was only 6 to 12 months in the four trials, which may be too short to detect a difference in outcomes. In the NIH trials, for example, patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone had a low rate of progression to renal failure in the first five years (approximately 10 percent, similar to that with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy) compared to 80 percent at 10 to 12 years (versus 10 percent with cyclophosphamide) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extended follow-up was provided in one of the trials, which included 42 patients at baseline and recruited 22 additional patients over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/19\">",
"     19",
"    </a>",
"    ]. At a median follow-up of 63 months, there was no significant difference between the two groups in creatinine clearance at study end (80",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the rate of doubling of the serum creatinine (6 versus 10 percent), and the number of patients who relapsed (11 versus 9 patients). Significantly more patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    developed infections requiring hospitalization, and leukopenia, amenorrhea and death only occurred in the cyclophosphamide group. The net effect was that MMF at extended follow-up was associated with a significant reduction in the risk of death or end-stage renal disease on extended follow-up (RR 0.44, 95% CI 0.23-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an international trial (ALMS) published after the meta-analysis and with more patients, MMF appeared to provide greater benefit than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    among black and Latino patients, and was comparable to monthly intravenous cyclophosphamide among white or Asian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This trial compared induction therapy with the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MMF (0.5 g twice daily in week one, 1.0 g twice daily in week two, and a target of 1.5 g twice daily thereafter or, if not tolerated, 1.0 g three times to two times daily). MMF was taken before meals and with a glass of water.",
"     </li>",
"     <li>",
"      Monthly intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (0.75",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      first dose, followed by five infusions of 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/m2).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients were also treated with oral daily glucocorticoids (using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or an equivalent dose of another preparation). The prednisolone regimen began at a dose of 60",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    tapered every two weeks by 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    until 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was reached, followed by tapering by 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    until 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was reached. Further tapering was allowed if the patient was stable for four weeks.",
"   </p>",
"   <p>",
"    The trial included 370 patients with lupus nephritis (LN): diffuse proliferative with or without membranous LN was present in 68 percent; focal proliferative with or without membranous LN in 16 percent; and pure membranous LN in 16 percent. The mean urine protein-to-creatinine ratio was 4.1 and the mean serum creatinine was 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 24 weeks, there was no difference between groups in the percentage of patients that achieved the primary or secondary end points. Seventy percent of patients in the MMF group had normal serum creatinine compared to 68 percent in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group. Twenty four percent of the MMF group had proteinuria less than 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      compared to 27 percent of the cyclophosphamide group.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      appeared to provide greater benefit among black and Latino patients; among 83 such patients, 60 percent responded to MMF compared to 39 percent who responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with an odds ratio 2.4 (95% CI, 1.1-5.4). A post hoc analysis revealed that among 131 Hispanic patients, more patients responded to MMF compared to cyclophosphamide (61 versus 39 percent with an odds ratio of 2.5 [95% CI, 1.2-5.1]).",
"     </li>",
"     <li>",
"      There was no difference in response rate between patients with focal or diffuse proliferative and those with membranous LN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=see_link\">",
"       \"Clinical features and therapy of membranous lupus nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The rate of adverse events was not different between the two groups; 96 versus 95 percent among patients who received MMF versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , respectively. For both treatment groups, the most common types of adverse events were infections and gastrointestinal disorders. Thirteen percent of patients withdrew from treatment with MMF because of adverse events compared to seven percent who withdrew from cyclophosphamide. There were nine deaths in the MMF group and five in the cyclophosphamide group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings from these trials suggest that an MMF regimen provides similar or perhaps greater efficacy and fewer adverse effects than a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimen, at least in patients with relatively normal kidney function and modest proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/23\">",
"     23",
"    </a>",
"    ]. The applicability of these findings to patients with more severe renal dysfunction is unknown. Furthermore, cyclophosphamide doses were not optimal in one study, and another used oral (not intravenous) cyclophosphamide.",
"   </p>",
"   <p>",
"    Another limitation of the above observations is the short duration of follow-up of 6 to 12 months in the four trials in the meta-analysis and the large subsequent trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In the NIH trials, for example, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone had a low rate of progression to renal failure in the first five years (approximately 10 percent, similar to that with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy) compared to 80 percent at 10 to 12 years (versus 10 percent with cyclophosphamide) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not widely used, a number of other drugs have been evaluated for induction therapy in patients with lupus nephritis. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , total lymphoid irradiation, and cytokine-directed therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/24-35\">",
"     24-35",
"    </a>",
"    ]. Data are insufficient to recommend any of these as primary therapy. Rituximab has also been used in patients with resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12345?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Rituximab for cyclophosphamide and MMF resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the relative efficacy of the different maintenance regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/13,36,37\">",
"     13,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9682692\">",
"    <span class=\"h2\">",
"     Cyclophosphamide versus azathioprine or mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;One trial included 59 patients with severe lupus nephritis (12 with focal proliferative, 46 with diffuse proliferative, and 1 with membranous lupus) who received induction therapy with intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (four to seven monthly doses) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months, then 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/13\">",
"     13",
"    </a>",
"    ]. Subsequently, patients continued low-dose oral prednisone (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), and were randomly assigned to one of the following: MMF (500 to 3000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), or intravenous cyclophosphamide (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    every three months). The median treatment duration was 24, 29, and 30 months for the cyclophosphamide, MMF, and azathioprine groups, respectively.",
"   </p>",
"   <p>",
"    The primary end points were renal and patient survival. Chronic renal failure was defined as a persistent doubling of the serum creatinine (of the lowest level attained with induction therapy) or if renal replacement therapy was required. At a median follow-up of three years, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the primary end points, five patients died (four and one in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and MMF groups, respectively), and five developed chronic renal failure (three in the cyclophosphamide group and one each in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and MMF groups).",
"     </li>",
"     <li>",
"      Based upon a Kaplan-Meier analysis at six years, the event-free survival rate for the composite end point (patient and renal survival) was significantly higher with MMF and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (90 and 80 percent, respectively) compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (45 percent).",
"     </li>",
"     <li>",
"      Seventeen patients (29 percent) had a renal relapse (eight, six, and three patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and MMF groups, respectively). The overall relapse-free rate was significantly higher with MMF than cyclophosphamide.",
"     </li>",
"     <li>",
"      Compared with the other two groups,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      was associated with significantly more hospital",
"      <span class=\"nowrap\">",
"       days/patient-year,",
"      </span>",
"      more infections, and a higher incidence of amenorrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concerns regarding the applicability of these results include the predominance of Hispanic (49 percent) and black (46 percent) patients (who typically have a worse prognosis) and the high rate of infections attributed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9682699\">",
"    <span class=\"h2\">",
"     Cyclosporine versus azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;One trial included 69 patients with diffuse proliferative or severe membranous lupus nephritis who received induction therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for three days) and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two weeks, tapered to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/36\">",
"     36",
"    </a>",
"    ]. Subsequently, patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (mean dose 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, adjusted to maintain trough levels 75 to 200",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, tapered to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day after one month if proteinuria &lt;1",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    All patients continued prednisone (tapered to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by six months, and to a mean dose of 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by 12 months). Therapy was administered for two years.",
"   </p>",
"   <p>",
"    Nine patients withdrew from the study due to side effects during the second year, and an additional 12 were lost to follow-up, with a similar distribution between the two treatment groups. At four year follow-up, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary outcome of lupus flares occurred with similar frequency in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (five renal, two extrarenal) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (seven renal, one extrarenal) groups. Two (cyclosporine) and three (azathioprine) flares occurred during the two years of active therapy.",
"     </li>",
"     <li>",
"      There was no difference in the change in creatinine clearance in the two groups.",
"     </li>",
"     <li>",
"      Reduction in proteinuria from &gt;2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      at baseline to &lt;0.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in both groups, but achieved earlier in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      group (6 versus 12 months).",
"     </li>",
"     <li>",
"      No patient died or reached end-stage renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9682732\">",
"    <span class=\"h2\">",
"     Azathioprine versus mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    was compared with MMF for maintenance therapy in three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/13,38,39\">",
"     13,38,39",
"    </a>",
"    ], with MAINTAIN Nephritis and ALMS Maintenance being the largest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MAINTAIN Nephritis Trial was a randomized open label trial that included 105 European patients (83 Caucasian) with biopsy-proven lupus nephritis and protein excretion exceeding 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/38\">",
"       38",
"      </a>",
"      ]. Diffuse proliferative was present in 61, focal proliferative LN in 33, and membranous LN in 11. All patients were treated with three daily 750 mg doses of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      followed by oral glucocorticoids plus six 500 mg intravenous doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      over ten weeks. On week 12, maintenance therapy was initiated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or MMF (2",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"      Renal relapse was defined as one or more of the following: recurrence or development of nephrotic syndrome; a 33 percent or greater increase in serum creatinine within one month; or a threefold increase in proteinuria accompanied by hematuria.",
"      <br/>",
"      <br/>",
"      At three years, there was no significant difference between the MMF and azathioprine groups in the rate of renal relapse (19 versus 25 percent), systemic flares, or steroid withdrawal. Adverse events were similar in the two groups except for leukopenia and anemia, which occurred more frequently in the azathioprine group (14 versus 2 patients).",
"     </li>",
"     <li>",
"      In the ALMS trial, a multinational two-phase study, 227 patients who had achieved remission with either MMF or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      were randomly assigned to MMF (1 g twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) as maintenance therapy for 36 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4985/abstract/39\">",
"       39",
"      </a>",
"      ]. Results from the induction phase of the ALMS trial are discussed above. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Among patients who responded to induction therapy with either MMF or cyclophosphamide, treatment failure at 36 months (defined by renal relapse, the need to intensify therapy, doubling of the serum creatinine, or death) was significantly lower with MMF compared with azathioprine groups (16 versus 32 percent). The superiority of MMF was independent of the type of induction therapy, race, or region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, MMF compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    was associated with a statistically and clinically significant reduction in relapse rate in the ALMS Maintenance Trial and a nonsignificant trend toward benefit in the MAINTAIN nephritis trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13073472\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy refers to the initial therapeutic regimen given in an attempt to produce remission of active disease. This is followed in almost all patients by maintenance therapy, usually with less toxic drugs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      National Institutes of Health (NIH) trials demonstrated higher remission and lower relapse rates but also a higher incidence of adverse events associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      without cyclophosphamide. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'NIH trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A trial by the Dutch Working Party demonstrated lower rates of relapse, doubling of the serum creatinine, and deaths or end-stage renal disease associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dutch Working Party on SLE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Lupus Nephritis Collaborative Study and the Euro-Lupus Nephritis Trial evaluated shorter courses",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      regimens. The Euro-Lupus Nephritis Trial suggested that a low dose cyclophosphamide induction regimen was as effective as a high dose regimen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Euro-Lupus Nephritis trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several trials have shown that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) provides similar or perhaps greater efficacy and fewer adverse effects than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , at least in patients with relatively normal kidney function and modest proteinuria, particularly among patients who refuse or cannot tolerate cyclophosphamide. Mycophenolate mofetil (MMF) may provide greater benefit than cyclophosphamide among black and Latino patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are limited data regarding the relative efficacy of the different maintenance regimens. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/1\">",
"      Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/2\">",
"      Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/3\">",
"      Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/4\">",
"      Lewis EJ. The treatment of lupus nephritis: revisiting Galen. Ann Intern Med 2001; 135:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/5\">",
"      Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/6\">",
"      Levey AS, Lan SP, Corwin HL, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/7\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/8\">",
"      Austin, HA, Fessler, BJ, Boumpas, DT, et al. Prognostic indicators supporting use of short courses of pulse immunosuppression for severe lupus nephritis (abstract). J Am Soc Nephrol 1995; 6:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/9\">",
"      Steinberg AD. The treatment of lupus nephritis. Kidney Int 1986; 30:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/10\">",
"      Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/11\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/12\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50:3934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/13\">",
"      Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/14\">",
"      Balow JE, Austin HA 3rd. Maintenance therapy for lupus nephritis--something old, something new. N Engl J Med 2004; 350:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/15\">",
"      Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/16\">",
"      Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/17\">",
"      Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/18\">",
"      Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/19\">",
"      Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/20\">",
"      Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/21\">",
"      Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/22\">",
"      Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/23\">",
"      Contreras G, Sosnov J. Role of mycophenolate mofetil in the treatment of lupus nephritis. Clin J Am Soc Nephrol 2007; 2:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/24\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/25\">",
"      Tam LS, Li EK, Leung CB, et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998; 91:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/26\">",
"      Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/27\">",
"      Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology (Oxford) 2000; 39:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/28\">",
"      Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/29\">",
"      Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000; 356:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/30\">",
"      Davis JC Jr, Austin H 3rd, Boumpas D, et al. A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998; 41:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/31\">",
"      Llorente L, Richaud-Patin Y, Garc&iacute;a-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/32\">",
"      Wada T, Yokoyama H, Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/33\">",
"      Zoja C, Corna D, Benedetti G, et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 1998; 53:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/34\">",
"      Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/35\">",
"      Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008; 47:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/36\">",
"      Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/37\">",
"      Mok CC, Ho CT, Siu YP, et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001; 38:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/38\">",
"      Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4985/abstract/39\">",
"      Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3061 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4985=[""].join("\n");
var outline_f4_55_4985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13073472\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2195479\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cyclophosphamide versus other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - NIH trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dutch Working Party on SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Duration of cyclophosphamide therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lupus Nephritis Collaborative Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Euro-Lupus Nephritis trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9682692\">",
"      Cyclophosphamide versus azathioprine or mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9682699\">",
"      Cyclosporine versus azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9682732\">",
"      Azathioprine versus mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13073472\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3061|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/48/14093\" title=\"figure 1\">",
"      Duration of CTX in lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/27/32187\" title=\"table 1\">",
"      Side effects pulse CTX in SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12345?source=related_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4986="Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults";
var content_f4_55_4986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4986/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4986/contributors\">",
"     Abbas E Kitabchi, PhD, MD, FACP, FACE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4986/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4986/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/55/4986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/55/4986/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/55/4986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS, also known as nonketotic hyperglycemia) are two of the most serious acute complications of diabetes. They are part of the spectrum of hyperglycemia and each represents an extreme in the spectrum.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of DKA and HHS will be reviewed here. The epidemiology, pathogenesis, and treatment of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DKA and HHS differ clinically according to the presence of ketoacidosis and usually the degree of hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The definitions proposed by the American Diabetes Association for DKA and HHS are shown in a table, along with criteria for classification of DKA as mild, moderate, or severe, based on the patient's arterial pH, serum bicarbonate, and mental status (",
"    <a class=\"graphic graphic_table graphicRef72111 \" href=\"UTD.htm?24/19/24892\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HHS, there is little or no ketoacid accumulation, the serum glucose concentration frequently exceeds 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (56",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      the plasma osmolality may reach 380",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      and neurologic abnormalities are frequently present (including coma in 25 to 50 percent of cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2-5\">",
"       2-5",
"      </a>",
"      ]. Most patients with HHS have an admission pH &gt;7.30, a serum bicarbonate &gt;20",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      a serum glucose &gt;600",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (33.3",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and test negative for ketones in serum and urine, although mild ketonemia may be present.",
"     </li>",
"     <li>",
"      DKA is characterized by the triad of hyperglycemia, anion gap metabolic acidosis, and ketonemia. Metabolic acidosis is often the major finding. The serum glucose concentration is usually greater than 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and less than 800",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2,6\">",
"       2,6",
"      </a>",
"      ]. However, serum glucose concentrations may exceed 900",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in patients with DKA who are comatose [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/7\">",
"       7",
"      </a>",
"      ]. In certain instances, such as DKA in the setting of starvation or pregnancy, or treatment with insulin prior to arrival in the emergency department, the glucose may be only mildly elevated. Factors that contribute to the lesser degree of hyperglycemia in DKA, compared with HHS, are discussed below. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Serum glucose'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant overlap between DKA and HHS has been reported in more than one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The typical total body deficits of water and electrolytes in DKA and HHS are compared in a table (",
"    <a class=\"graphic graphic_table graphicRef76060 \" href=\"UTD.htm?35/3/35899\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRECIPITATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A precipitating event can usually be identified in patients with DKA or HHS (",
"    <a class=\"graphic graphic_table graphicRef64374 \" href=\"UTD.htm?35/22/36205\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/1,2,4,8,9,11\">",
"     1,2,4,8,9,11",
"    </a>",
"    ]. The most common events are infection (often pneumonia or urinary tract infection) and discontinuation of or inadequate insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/12\">",
"     12",
"    </a>",
"    ]. Compromised water intake due to underlying medical conditions, particularly in elderly patients, can promote the development of severe dehydration and HHS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/8,13,14\">",
"     8,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other conditions and factors associated with DKA and HHS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute major illnesses such as myocardial infarction, cerebrovascular accident, or pancreatitis.",
"     </li>",
"     <li>",
"      New onset type 1 diabetes, in which DKA is a common presentation.",
"     </li>",
"     <li>",
"      Drugs that affect carbohydrate metabolism, including glucocorticoids, higher dose thiazide diuretics, sympathomimetic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/15\">",
"       15",
"      </a>",
"      ], and second-generation antipsychotic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cocaine use, which has been associated with recurrent DKA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Psychological problems associated with eating disorders and purposeful insulin omission, particularly in young patients with type 1 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/19\">",
"       19",
"      </a>",
"      ]. Factors that may lead to insulin omission in younger patients include fear of weight gain, fear of hypoglycemia, rebellion from authority, and the stress of chronic disease.",
"     </li>",
"     <li>",
"      Poor compliance with the insulin regimen. Compliance issues, with substance abuse as a contributory factor, is the main cause of decompensated diabetes in urban African Americans [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malfunction of continuous subcutaneous insulin infusion devices (CSII) was reported in the early 1980s [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/21\">",
"       21",
"      </a>",
"      ]. However, the lack of more recent reports suggests that this risk may no longer be of concern [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;DKA usually evolves rapidly, over a 24-hour period. In contrast, symptoms of HHS develop more insidiously with polyuria, polydipsia, and weight loss, often persisting for several days before hospital admission.",
"   </p>",
"   <p>",
"    The earliest symptoms of marked hyperglycemia are polyuria, polydipsia, and weight loss. As the degree or duration of hyperglycemia progresses, neurologic symptoms, including lethargy, focal signs, and obtundation, which can progress to coma in later stages, can be seen. Neurological symptoms are most common in HHS, while hyperventilation and abdominal pain are primarily limited to patients with DKA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both DKA and HHS are medical emergencies that require prompt recognition and management. An initial history and rapid but careful physical examination should focus on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway, breathing, and circulation (ABC) status",
"     </li>",
"     <li>",
"      Mental status",
"     </li>",
"     <li>",
"      Possible precipitating events (eg, source of infection, myocardial infarction)",
"     </li>",
"     <li>",
"      Volume status",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic symptoms and plasma osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic deterioration primarily occurs in patients with an",
"    <strong>",
"     effective",
"    </strong>",
"    plasma osmolality above 320 to 330",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/4,6,10,11\">",
"     4,6,10,11",
"    </a>",
"    ]. Mental obtundation and coma are more frequent in HHS than DKA because of the usually greater degree of hyperosmolality in HHS (",
"    <a class=\"graphic graphic_table graphicRef72111 \" href=\"UTD.htm?24/19/24892\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, some patients with HHS have focal neurologic signs (hemiparesis or hemianopsia)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. Mental obtundation may occur in patients with DKA, who have lesser degrees of hyperosmolality, when severe acidosis is also present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the calculation of effective plasma osmolality, the urea concentration is not taken into account because urea is freely permeable and its accumulation does not induce major changes in intracellular (including brain) volume or the osmotic gradient across the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effective plasma osmolality (Posm, in",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    can be estimated from either of the following equations:",
"   </p>",
"   <p>",
"    &nbsp;Effective Posm &nbsp;= &nbsp;[2 &nbsp;x &nbsp;Na",
"    <span class=\"nowrap\">",
"     (meq/L)]",
"    </span>",
"    &nbsp;+ &nbsp;[glucose",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    &nbsp;&divide; &nbsp;18]",
"   </p>",
"   <p>",
"    &nbsp;Effective Posm &nbsp;= &nbsp;Measured Posm &nbsp;- &nbsp;[BUN",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    &nbsp;&divide; &nbsp;28]",
"   </p>",
"   <p>",
"    Where Na is the serum sodium concentration, the multiple 2 accounts for the osmotic contribution of the anions accompanying sodium (primarily chloride and bicarbonate), and 18 and 28 are conversion factors from units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    into",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Where standard units are used, the following equations apply:",
"   </p>",
"   <p>",
"    &nbsp;Effective Posm &nbsp;= &nbsp;[2 &nbsp;x &nbsp;Na",
"    <span class=\"nowrap\">",
"     (mmol/L)]",
"    </span>",
"    &nbsp;+ &nbsp;glucose",
"    <span class=\"nowrap\">",
"     (mmol/L)",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Effective Posm &nbsp;= &nbsp;Measured Posm &nbsp;- &nbsp;BUN or blood urea",
"    <span class=\"nowrap\">",
"     (mmol/L)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Importance of osmotic diuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rise in plasma osmolality in DKA and HHS is only in part due to the rise in serum glucose. The increase in plasma osmolality pulls water out of the cells, which reduces the plasma osmolality toward normal and lowers the serum sodium. The marked hyperosmolality seen in HHS is primarily due to the glucose osmotic diuresis that causes water loss in excess of sodium and potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These principles and the importance of effective plasma osmolality in the development of neurologic symptoms are illustrated by observations in diabetic patients with end-stage renal disease. These patients can develop severe hyperglycemia, with serum glucose concentrations that can exceed 1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (56 to 83",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    However, because there is little or no osmotic diuresis, the rise in plasma osmolality is limited, hyponatremia is present, and there are few or no neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of stupor or coma in diabetic patients with an effective plasma osmolality lower than 320",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    demands immediate consideration of other causes of the mental status change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abdominal pain in DKA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DKA may present with nausea, vomiting, and abdominal pain; although more common in children, these symptoms can be seen in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/32\">",
"     32",
"    </a>",
"    ]. Abdominal pain is unusual in HHS. In a review of 189 consecutive episodes of DKA and 11 episodes of HHS, abdominal pain was reported in 46 percent of patients with DKA compared with none of the patients with HHS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/33\">",
"     33",
"    </a>",
"    ]. The presence of abdominal pain was associated with the severity of the metabolic acidosis (occurring in 86 and 13 percent of those with a serum bicarbonate &le;5 and &ge;15",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    respectively) but did not correlate with the severity of hyperglycemia or dehydration.",
"   </p>",
"   <p>",
"    Possible causes of abdominal pain include delayed gastric emptying and ileus induced by the metabolic acidosis and associated electrolyte abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/11\">",
"     11",
"    </a>",
"    ]. Other causes for abdominal pain should be sought when it occurs in the absence of severe metabolic acidosis and when it persists after the resolution of ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of volume depletion are common in both DKA and HHS, including decreased skin turgor, dry axillae and oral mucosa, low jugular venous pressure and, if severe, hypotension. Neurologic findings, noted above, also may be seen, particularly in patients with HHS. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Neurologic symptoms and plasma osmolality'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with DKA may have a fruity odor (due to exhaled acetone and similar to the odor of nail polish remover), and deep respirations reflecting the compensatory hyperventilation (called Kussmaul respirations).",
"   </p>",
"   <p>",
"    Fever is rare even in the presence of infection, because of peripheral vasoconstriction due to hypovolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia and hyperosmolality are the two primary laboratory findings in patients with DKA or HHS; patients with DKA also have a high anion gap metabolic acidosis. Most patients also have acute elevations in the blood urea nitrogen (BUN) and serum creatinine concentration, which reflect the reduction in glomerular filtration rate induced by hypovolemia.",
"   </p>",
"   <p>",
"    A variety of additional laboratory tests may be affected. The impact of hyperglycemia, insulin deficiency, osmotic diuresis, and fluid intake in individual patients leads to variability in laboratory findings, depending upon the relative importance of these factors.",
"   </p>",
"   <p>",
"    The initial laboratory evaluation of a patient with suspected DKA or HHS should include determination of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum glucose",
"     </li>",
"     <li>",
"      Serum electrolytes (with calculation of the anion gap), BUN, and serum creatinine",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Urinalysis, and urine ketones by dipstick",
"     </li>",
"     <li>",
"      Plasma osmolality",
"     </li>",
"     <li>",
"      Serum ketones (if urine ketones are present)",
"     </li>",
"     <li>",
"      Arterial blood gas (if urine ketones or anion gap are present)",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing, such as cultures of urine, sputum, and blood, serum lipase and amylase, and chest x-ray, should be performed on a case-by-case basis.",
"   </p>",
"   <p>",
"    Measurement of A1C may be useful in determining whether the acute episode is the culmination of an evolutionary process in previously undiagnosed or poorly controlled diabetes or a truly acute episode in an otherwise well-controlled patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum glucose concentration frequently exceeds 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (56",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in HHS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ], but is generally below 800",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Euglycemic DKA, in which the serum glucose is normal or near normal but the patient requires insulin therapy for the clearance of ketoacidosis, has been described, particularly in the presence of poor oral intake or pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two factors contribute to the lesser degree of hyperglycemia in DKA compared with HHS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with DKA often present early with symptoms of ketoacidosis (such as shortness of breath and abdominal pain), rather than late with those of hyperosmolality.",
"     </li>",
"     <li>",
"      Patients with DKA tend to be young and to have a glomerular filtration rate that, at least in the first five years, may be as much as 50 percent above normal. As a result, they have a much greater capacity to excrete glucose than the usually older patients with HHS, thereby limiting the degree of hyperglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of diabetic nephropathy\", section on 'Glomerular filtration rate'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with end-stage renal disease can develop severe hyperglycemia, but develop few if any neurologic symptoms, because there is no osmotic diuresis that is largely responsible for the marked rise in plasma osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Importance of osmotic diuresis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum ketones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three ketone bodies are produced in DKA: acetoacetic acid, which is the only true ketoacid; beta-hydroxybutyric acid, a hydroxyacid formed from the reduction of acetoacetic acid; and acetone, which is derived from the decarboxylation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    . Acetone is a true ketone but is chemically neutral and therefore not an acid. Urine ketone bodies are detected by a dipstick. Testing for serum ketones is performed if urine testing is positive, using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    (Acetest) tablets or reagent sticks. A 4+ reaction with serum diluted 1:1 is strongly suggestive of ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     False negative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    reacts with acetoacetate and acetone, but not with beta-hydroxybutyrate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. This is important because beta-hydroxybutyrate is the predominant ketone, particularly in severe DKA. It is therefore possible, although unusual, to have a negative serum nitroprusside reaction in the presence of severe ketosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/11,36\">",
"     11,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An indirect method to circumvent the masking of ketoacidosis is to add a few drops of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    to a urine specimen. This will nonenzymatically convert beta-hydroxybutyrate to acetoacetate, which will then be detectable by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/38\">",
"     38",
"    </a>",
"    ]. An alternative is to directly measure beta-hydroxybutyrate in the blood; monitors are available to measure beta-hydroxybutyrate at the bedside, but this assay may not be available in many hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     False positive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfhydryl drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    , interact with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    reagent and can lead to a false positive ketone test [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, a positive nitroprusside test cannot be reliably interpreted in patients treated with these drugs and direct measurement of beta-hydroxybutyrate is recommended. If it is not available, the diagnosis of DKA in this setting should be made on the basis of clinical presentation and an otherwise unexplained high anion gap metabolic acidosis in association with hyperglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anion gap metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum bicarbonate concentration in DKA is reduced to a variable degree, ranging from mild to severe. In contrast, the serum bicarbonate concentration is normal or only mildly reduced in HHS.",
"   </p>",
"   <p>",
"    The sine qua non of DKA is an elevated anion gap metabolic acidosis, due to the production and accumulation of beta-hydroxybutyrate and acetoacetate. Compensatory hyperventilation results in a fall in the partial pressure of CO2 that minimizes the fall in arterial pH. The arterial pH in DKA is less than 7.30 and can be lower than 6.90.",
"   </p>",
"   <p>",
"    The severity of the metabolic acidosis is dependent upon a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of ketoacid production.",
"     </li>",
"     <li>",
"      The duration of increased ketoacid production. The acidosis will be less severe in patients who present early due, as an example, to abdominal pain or an underlying infection that precipitated the ketoacidosis.",
"     </li>",
"     <li>",
"      The rate of acid excretion in the urine [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/42\">",
"       42",
"      </a>",
"      ]. Patients with relatively normal renal function can markedly increase acid excretion, thereby minimizing the severity of the acidosis. The magnitude of this effect was illustrated in a study of patients with DKA: ketone production averaged 51",
"      <span class=\"nowrap\">",
"       meq/hour,",
"      </span>",
"      while net acid excretion with the ketoacid anions averaged 15",
"      <span class=\"nowrap\">",
"       meq/hour",
"      </span>",
"      or 30 percent of the ketoacid load [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/43\">",
"       43",
"      </a>",
"      ]. The conversion of acetoacetic acid to acetone can neutralize another 15 to 25 percent of the acid load [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serum anion gap provides an estimate of the quantity of unmeasured anions in the serum, such as albumin and, in DKA, ketoacids. It is calculated by subtracting the major measured anions (chloride and bicarbonate) from the major measured cation (sodium):",
"   </p>",
"   <p>",
"    &nbsp; Serum anion gap &nbsp;= &nbsp;Serum sodium &nbsp;- &nbsp;(serum chloride + bicarbonate)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with DKA usually present with a serum anion gap greater than 20",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, the increase in anion gap is variable, being determined by two factors: the rate and duration of ketoacid production, and the rate of loss of ketoacid anions in the urine. With respect to ketonuria, excretion of the sodium and potassium salts of beta-hydroxybutyrate and acetoacetate lowers the serum anion gap without affecting the serum bicarbonate concentration and therefore the degree of acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/42,45\">",
"     42,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of ketoacid anions excreted depends upon the degree to which glomerular filtration is maintained. Patients with relatively normal renal function can lose large quantities of ketoacids (as much as 30 percent of the ketoacid load [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/43\">",
"     43",
"    </a>",
"    ]), which minimizes the elevation in anion gap. Rarely, patients excrete so much ketoacids that they present with only a small elevation in serum anion gap [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, all patients, except those with end-stage renal disease, will develop a normal anion gap during the treatment phase of DKA because of the urinary ketoacid anion losses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/46\">",
"     46",
"    </a>",
"    ]. These principles are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link&amp;anchor=H5#H5\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Urinary loss of unmeasured anions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measured serum sodium concentration in uncontrolled diabetes mellitus is variable, as factors are present that can both lower and raise the measured value. The final serum sodium concentration will reflect the balance between dilution of sodium due to osmotic water movement out of the cells, and concentration of sodium due to glucosuria-induced osmotic diuresis resulting in water loss in excess of sodium.",
"   </p>",
"   <p>",
"    Physiologic calculations suggest that the serum sodium concentration should fall by 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 62",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    rise in the serum concentration of glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/47\">",
"     47",
"    </a>",
"    ]. However, this standard correction factor was not verified experimentally. In an experimental model, hyperglycemia was induced in six healthy subjects by the administration of somatostatin (to block endogenous insulin secretion) and a hypertonic dextrose solution [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nonlinear relationship was observed between the changes in the glucose and sodium concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 1:62 ratio applied when the serum glucose concentration was less than 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (22.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      At higher glucose concentrations, there was a greater reduction in the serum sodium concentration (1:25 ratio, a 4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      reduction in serum sodium per 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      further increase in serum glucose).",
"     </li>",
"     <li>",
"      An overall ratio of 1:42 (a 2.4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      reduction in the serum sodium concentration for every 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.5",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      elevation in the serum glucose) provided a better estimate of this association than the usual 1:62 ratio.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The direct effect of hyperglycemia on the serum sodium concentration is counteracted to a variable degree by the glucosuria-induced osmotic diuresis. The diuresis results in water loss in excess of sodium and potassium, which will tend to raise the serum sodium concentration and plasma osmolality unless there is a comparable increase in water intake. Some patients with uncontrolled diabetes have such a marked osmotic diuresis that, at presentation, the serum sodium concentration is increased and the serum osmolality is markedly elevated. Inadequate water intake prevents partial correction of the hyperosmolality and is a particular problem in hot weather and in elderly patients who may have an impaired thirst mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above calculations are best used to estimate how much the serum sodium concentration will rise as the hyperglycemia is corrected. The administration of insulin drives glucose and water into the cells, reversing the initial direction of water movement and raising the serum sodium concentration.",
"   </p>",
"   <p>",
"    Most patients with DKA and HHS are mildly hyponatremic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/50\">",
"     50",
"    </a>",
"    ]. However, patients with HHS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/51\">",
"     51",
"    </a>",
"    ] who have a marked osmotic diuresis may have a normal or even elevated serum sodium concentration despite a serum glucose concentration that can exceed 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (56",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    These patients are extremely hyperosmolar and often have neurologic symptoms that can include seizures and coma. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Neurologic symptoms and plasma osmolality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, the osmotic diuresis is attenuated in patients with advanced underlying renal disease (usually due to diabetic nephropathy) and does not occur in patients already on maintenance dialysis. In this setting, there is hyperglycemia-induced hyponatremia (with the serum sodium concentration falling below 125",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in many cases), only a modest elevation in the plasma osmolality (due to the counterbalancing effects of hyperglycemia and hyponatremia), and usually no neurologic symptoms despite marked hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pseudohyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with uncontrolled diabetes have marked hyperlipidemia and lactescent serum. In this setting, each liter of serum contains less water and therefore less sodium. As a result, the measured serum sodium concentration will fall, even though the physiologically important serum water sodium concentration and plasma osmolality are not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Ion-selective electrodes will reveal a normal serum sodium concentration if an instrument employing direct potentiometry is used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of therapy on the serum sodium concentration in DKA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DKA or HHS, at presentation, have a potassium deficit that averages 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/50,54\">",
"     50,54",
"    </a>",
"    ]. A number of factors contribute to this deficit, particularly increased urinary losses due both to the glucose osmotic diuresis and to the need to maintain electroneutrality as ketoacid anions are excreted. Gastrointestinal losses and the loss of potassium from the cells due to glycogenolysis and proteolysis also may play a contributory role.",
"   </p>",
"   <p>",
"    Despite these potassium losses, the serum potassium concentration is usually normal or, in one-third of patients, elevated on admission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2,5,50,55\">",
"     2,5,50,55",
"    </a>",
"    ]. It is thought that hyperosmolality and insulin deficiency are primarily responsible for the relative rise in the serum potassium concentration in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/15,29,50\">",
"     15,29,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rise in plasma osmolality leads to osmotic water movement out of the cells. This can promote the parallel movement of potassium into the extracellular fluid by two mechanisms: the rise in cell potassium concentration induced by water loss favors passive potassium exit through potassium channels in the cell membrane, and the frictional forces between solvent (water) and solute can result in potassium being carried out through the water pores in the cell membrane (a process that is called solvent drag) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since insulin normally promotes potassium uptake by the cells, insulin deficiency also contributes to elevated serum potassium levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acidemia probably does not play a major role in the elevated serum potassium associated with DKA. Although a transcellular exchange of potassium with hydrogen ions resulting in a rise in serum potassium occurs in most forms of metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/56\">",
"     56",
"    </a>",
"    ], it does not appear to play a major role in ketoacidosis (or lactic acidosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/50,56-58\">",
"     50,56-58",
"    </a>",
"    ]. The greater importance of hyperosmolality and insulin deficiency is illustrated by the observation that hyperkalemia also occurs in HHS despite the absence of acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=see_link&amp;anchor=H3#H3\">",
"     \"Potassium balance in acid-base disorders\", section on 'Metabolic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin therapy lowers the potassium concentration and may cause severe hypokalemia, particularly in patients with a normal or low serum potassium concentration at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, careful monitoring and timely administration of potassium supplementation are essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Potassium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serum phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncontrolled hyperglycemia are typically in negative phosphate balance because of decreased phosphate intake and phosphaturia caused by osmotic diuresis. Despite phosphate depletion, the serum phosphate concentration at presentation is usually normal or even high because both insulin deficiency and metabolic acidosis cause a shift of phosphate out of the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This transcellular shift is reversed and the true state of phosphate balance is unmasked after treatment with insulin. In a review of 69 episodes of DKA, the mean serum phosphate concentration fell from 9.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at presentation to 2.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at 12 hours, and some patients had values as low as 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Phosphate depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serum amylase and lipase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum amylase and lipase are the standard tests to diagnose acute pancreatitis, which may precipitate DKA, but both are often elevated in patients with DKA who do not have pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. As a result, the diagnosis of pancreatitis in patients with DKA should be based upon clinical findings and imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\", section on 'Radiologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms for hyperamylasemia and hyperlipasemia in DKA are not well defined, but the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 100 consecutive cases of DKA, 11 had acute pancreatitis as confirmed by CT scan; the most common causes were hypertriglyceridemia and alcohol intake [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/66\">",
"       66",
"      </a>",
"      ]. Two of the 10 evaluable patients (one was comatose) did not have abdominal pain.",
"     </li>",
"     <li>",
"      In a review of 134 consecutive episodes of DKA in patients with no CT evidence of acute pancreatitis, elevations of serum amylase and lipase (threefold or higher in some patients) were seen in 17 and 24 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/61\">",
"       61",
"      </a>",
"      ]. Abdominal pain was present in 19 percent of the patients in this series.",
"     </li>",
"     <li>",
"      The source of these nonspecific amylase elevations is most often salivary, though may also be pancreatic [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/62,63,65\">",
"       62,63,65",
"      </a>",
"      ]. The source of nonspecific lipase elevations is not known.",
"     </li>",
"     <li>",
"      The rise in amylase correlates with pH and plasma osmolality, while the rise in lipase correlates only with plasma osmolality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/61\">",
"       61",
"      </a>",
"      ]. Peak values are seen within 24 hours of presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with hyperglycemic emergencies present with leukocytosis, which is proportional to the degree of ketonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/15,67\">",
"     15,67",
"    </a>",
"    ]. Leukocytosis unrelated to infection may occur as a result of hypercortisolemia and increased catecholamine secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/68\">",
"     68",
"    </a>",
"    ]. However, a white blood cell count greater than",
"    <span class=\"nowrap\">",
"     25,000/microL",
"    </span>",
"    or a band count greater than 10 percent may designate infection and indicates a need for further work up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DKA or HHS may present with marked hyperlipidemia and lactescent serum. In a study of 13 patients with DKA, the mean plasma triglyceride and cholesterol levels on admission were 574",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.5",
"    <span class=\"nowrap\">",
"     mol/L)",
"    </span>",
"    and 212",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/70\">",
"     70",
"    </a>",
"    ]. Triglycerides fell below 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in 24 hours with insulin therapy.",
"   </p>",
"   <p>",
"    Insulin is the most anti-lipolytic hormone. Insulin deficiency, combined with elevated levels of lipolytic hormones (catecholamines, growth hormone, ACTH, and glucagon) in DKA and HHS result in accumulation of free fatty acids. The increase in serum fatty acids leads to inhibition of glycolysis, production of triacylglycerol, and increased ketones by fatty acid entry into mitochondria where they serve as a substrate for ketogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of metabolic causes of acidosis and coma are depicted in a table (",
"    <a class=\"graphic graphic_table graphicRef72299 \" href=\"UTD.htm?27/17/27933\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Alcoholic and fasting ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholic ketoacidosis (AKA) and starvation ketosis are other causes of ketoacidosis. The acidosis can be relatively severe in alcoholic ketoacidosis. In comparison, ketoacid levels in fasting ketoacidosis do not exceed 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with prolonged fasting alone, which means that the serum bicarbonate concentration is typically above 14",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=see_link\">",
"     \"Alcoholic and fasting ketoacidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of ketoacidosis without hyperglycemia in an alcoholic patient is virtually diagnostic of AKA. However, modest elevations in serum glucose have been reported in alcoholic ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/72\">",
"     72",
"    </a>",
"    ]. This may reflect underlying unrecognized diabetes or a catecholamine-mediated stress response. Measurement of A1C may be helpful to detect chronic hyperglycemia.",
"   </p>",
"   <p>",
"    In addition to fasting, a case report suggested a relationship between low carbohydrate diet and ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/55/4986/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Anion gap acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;DKA must also be distinguished from other causes of high anion gap metabolic acidosis including lactic acidosis (which can be induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , particularly in patients with impaired renal function); ingestion of drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , methanol, and ethylene glycol; and advanced chronic kidney disease. None of these disorders causes ketoacidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=see_link\">",
"       \"Patient information: Diabetic ketoacidosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25699?source=see_link\">",
"       \"Patient information: Hyperosmolar nonketotic coma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although part of a spectrum of diabetic complications, diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) primarily differ according to the presence of ketoacidosis and the degree of hyperglycemia. Neurologic complications, related to higher glucose levels and serum osmolality, are more common in HHS. The triad of DKA consists of hyperglycemia, anion gap metabolic acidosis, and ketonemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A precipitating event can usually be identified in patients with DKA or HHS. The most common are infection (most often pneumonia or urinary tract infection) and discontinuation of or inadequate insulin therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of patients with hyperglycemic crises should include assessment of cardiorespiratory status, volume status, and mental status. Abdominal pain is common in DKA but not in HHS, and requires evaluation if it does not resolve with treatment of the acidosis. Neurologic symptoms, which may include focal findings, are more often seen in HHS and primarily occur when the effective serum osmolality is greater than 320 to 330",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      The presence of stupor or coma in diabetic patients with an effective serum osmolality below 320",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      demands immediate consideration of other causes of the mental status change. Infection can occur without fever. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucose concentrations in DKA are usually less than 800",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      but often exceed 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (56",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in HHS. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Serum glucose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three ketone bodies are produced in DKA: one ketoacid (acetoacetic acid), one hydroxyacid (beta-hydroxybutyric acid), and one neutral ketone (acetone). The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      test (Acetest) may give false negative readings since it does not detect beta-hydroxybutyrate which may be the major ketone body present. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Serum ketones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DKA usually present with a serum anion gap greater than 20",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      However, the increase in anion gap is variable, being determined by two factors: the rate and duration of ketoacid production, and the rate of loss of ketoacid anions in the urine. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anion gap metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serum sodium concentration in DKA and HHS reflects the balance between the dilutional effect of water moving out of cells in response to the hyperglycemia-induced increase in serum osmolality and the increase in water excretion due to the glucosuria-induced osmotic diuresis. Most patients are mildly hyponatremic, but patients who have a marked osmotic diuresis may have a normal or even elevated serum sodium concentration. Hypertriglyceridemia can interfere with measurement of serum sodium with certain assays, resulting in falsely low values. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DKA or HHS have a potassium deficit that averages 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      Despite this deficit, the serum potassium concentration is often elevated at presentation as both insulin deficiency and hyperosmolality result in potassium movement out of the cells into the extracellular fluid. Insulin therapy lowers the potassium concentration and may cause severe hypokalemia, particularly in patients with a normal or low serum potassium concentration at presentation. Thus, careful monitoring and timely administration of potassium supplementation are essential. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Serum potassium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum amylase and lipase levels are elevated in 15 to 25 percent of patients with DKA and, in most cases, do not reflect acute pancreatitis. The diagnosis of pancreatitis should be based upon clinical findings and confirmed by imaging. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Serum amylase and lipase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ketoacidosis may also be caused by alcohol abuse or fasting. Other causes of an anion gap acidosis include lactic acidosis, ingestion of drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , methanol, and ethylene glycol, and advanced chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.809-815.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/2\">",
"      Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/3\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/4\">",
"      Daugirdas JT, Kronfol NO, Tzamaloukas AH, Ing TS. Hyperosmolar coma: cellular dehydration and the serum sodium concentration. Ann Intern Med 1989; 110:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/5\">",
"      Kitabchi AE, Young R, Sacks H, Morris L. Diabetic ketoacidosis: reappraisal of therapeutic approach. Annu Rev Med 1979; 30:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/6\">",
"      Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet 1973; 2:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/7\">",
"      Morris LR, Kitabchi AE. Efficacy of low-dose insulin therapy for severely obtunded patients in diabetic ketoacidosis. Diabetes Care 1980; 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/8\">",
"      Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med 1990; 6:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/9\">",
"      Szeto CC, Li KY, Ko GT, et al. Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance. Int J Clin Pract 1997; 51:476.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: Physiologic versus pharmacologic doses of insulin and their routes of administration. In: Handbook of Diabetes Mellitus, Brownlee M (Ed), Garland ATPM Press, New York 1981. p.95.",
"    </li>",
"    <li>",
"     Kitabchi AE, Razavi L.Hyperglycemic Crises: Diabetic Ketoacidosis (DKA), And Hyperglycemic Hyperosmolar State (HHS). In: file://www.endotext.org/diabetes/diabetes24/diabetesframe24.htm (Accessed on January 30, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/12\">",
"      Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care 2011; 34:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/13\">",
"      Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987; 35:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/14\">",
"      Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, et al. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 1991; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Murphy MB. Consequences of insulin deficiency. In: Atlas of Diabetes, 4th, Skyler J.  (Ed), Springer US, New York 2012. p.39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/16\">",
"      Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/17\">",
"      Warner EA, Greene GS, Buchsbaum MS, et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med 1998; 158:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/18\">",
"      Nyenwe EA, Loganathan RS, Blum S, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract 2007; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/19\">",
"      Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994; 17:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/20\">",
"      Umpierrez GE, Kelly JP, Navarrete JE, et al. Hyperglycemic crises in urban blacks. Arch Intern Med 1997; 157:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/21\">",
"      Peden NR, Braaten JT, McKendry JB. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes Care 1984; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/22\">",
"      Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/23\">",
"      Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 1995; 79:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/24\">",
"      Maccario M. Neurological dysfunction associated with nonketotic hyperglycemia. Arch Neurol 1968; 19:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/25\">",
"      Guisado R, Arieff AI. Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain. Metabolism 1975; 24:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/26\">",
"      Lavin PJ. Hyperglycemic hemianopia: a reversible complication of non-ketotic hyperglycemia. Neurology 2005; 65:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/27\">",
"      Harden CL, Rosenbaum DH, Daras M. Hyperglycemia presenting with occipital seizures. Epilepsia 1991; 32:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/28\">",
"      Nyenwe EA, Razavi LN, Kitabchi AE, et al. Acidosis: the prime determinant of depressed sensorium in diabetic ketoacidosis. Diabetes Care 2010; 33:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/29\">",
"      DeFronzo, RA, Matzuda, M, Barret, E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/30\">",
"      Al-Kudsi RR, Daugirdas JT, Ing TS, et al. Extreme hyperglycemia in dialysis patients. Clin Nephrol 1982; 17:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/31\">",
"      Popli S, Leehey DJ, Daugirdas JT, et al. Asymptomatic, nonketotic, severe hyperglycemia with hyponatremia. Arch Intern Med 1990; 150:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/32\">",
"      Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc 1992; 40:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/33\">",
"      Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care 2002; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/34\">",
"      Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J 1973; 2:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/35\">",
"      Burge MR, Hardy KJ, Schade DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. J Clin Endocrinol Metab 1993; 76:1192.",
"     </a>",
"    </li>",
"    <li>",
"     Eisenbarth GS, Polonsky KS, Buse JB. Type 1 diabetes mellitus: Acute diabetic emergencies: Diabetic ketoacidosis. In: Williams Textbook of Endocrinology, Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (Eds), Elsevier Science, Philadelphia 2003. p.1500.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/37\">",
"      Marliss EB, Ohman JL Jr, Aoki TT, Kozak GP. Altered redox state obscuring ketoacidosis in diabetic patients with lactic acidosis. N Engl J Med 1970; 283:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/38\">",
"      Narins RG, Jones ER, Stom MC, et al. Diagnostic strategies in disorders of fluid, electrolyte and acid-base homeostasis. Am J Med 1982; 72:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/39\">",
"      Porter WH, Yao HH, Karounos DG. Laboratory and clinical evaluation of assays for beta-hydroxybutyrate. Am J Clin Pathol 1997; 107:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/40\">",
"      Fulop M, Murthy V, Michilli A, et al. Serum beta-hydroxybutyrate measurement in patients with uncontrolled diabetes mellitus. Arch Intern Med 1999; 159:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/41\">",
"      Csako G, Elin RJ. Unrecognized false-positive ketones from drugs containing free-sulfhydryl group(s). JAMA 1993; 269:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/42\">",
"      Adrogu&eacute; HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/43\">",
"      Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/44\">",
"      Fulop M. The treatment of severely uncontrolled diabetes mellitus. Adv Intern Med 1984; 29:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/45\">",
"      Adrogu&eacute; HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/46\">",
"      Oh MS, Carroll HJ, Goldstein DA, Fein IA. Hyperchloremic acidosis during the recovery phase of diabetic ketosis. Ann Intern Med 1978; 89:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/47\">",
"      Katz MA. Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression. N Engl J Med 1973; 289:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/48\">",
"      Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/49\">",
"      Phillips PA, Bretherton M, Johnston CI, Gray L. Reduced osmotic thirst in healthy elderly men. Am J Physiol 1991; 261:R166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/50\">",
"      Adrogu&eacute; HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/51\">",
"      Khardori R, Soler NG. Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review. Am J Med 1984; 77:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/52\">",
"      Kaminska ES, Pourmotabbed G. Spurious laboratory values in diabetic ketoacidosis and hyperlipidemia. Am J Emerg Med 1993; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/53\">",
"      Rumbak MJ, Hughes TA, Kitabchi AE. Pseudonormoglycemia in diabetic ketoacidosis with elevated triglycerides. Am J Emerg Med 1991; 9:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/54\">",
"      Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978; 88:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/55\">",
"      Atchley DW, Loeb RF, Richards DW, et al. ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy. J Clin Invest 1933; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/56\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/57\">",
"      Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/58\">",
"      Adrogu&eacute; HJ, Chap Z, Ishida T, Field JB. Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs. J Clin Invest 1985; 75:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/59\">",
"      Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA 1966; 196:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/60\">",
"      Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/61\">",
"      Yadav D, Nair S, Norkus EP, Pitchumoni CS. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol 2000; 95:3123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/62\">",
"      Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet 1977; 1:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/63\">",
"      Vinicor F, Lehrner LM, Karn RC, Merritt AD. Hyperamylasemia in diabetic ketoacidosis: sources and significance. Ann Intern Med 1979; 91:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/64\">",
"      Vantyghem MC, Haye S, Balduyck M, et al. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol 1999; 36:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/65\">",
"      Kjaergaard JJ, Salling N, Magid E, Ditzel J. Serum amylase during recovery from diabetic ketoacidosis. Diabete Metab 1984; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/66\">",
"      Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol 2000; 95:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/67\">",
"      Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/68\">",
"      Razavi, L, Taheri, E, Larijani, B, et al. Catecholamine-induced leukocytosis in acute hypoglycemic stress. J Investig Med 2007; 55:S262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/69\">",
"      Slovis CM, Mork VG, Slovis RJ, Bain RP. Diabetic ketoacidosis and infection: leukocyte count and differential as early predictors of serious infection. Am J Emerg Med 1987; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/70\">",
"      Weidman SW, Ragland JB, Fisher JN Jr, et al. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res 1982; 23:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/71\">",
"      Reichard GA Jr, Owen OE, Haff AC, et al. Ketone-body production and oxidation in fasting obese humans. J Clin Invest 1974; 53:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/72\">",
"      Wrenn KD, Slovis CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med 1991; 91:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/55/4986/abstract/73\">",
"      Shah P, Isley WL. Ketoacidosis during a low-carbohydrate diet. N Engl J Med 2006; 354:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1792 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4986=[""].join("\n");
var outline_f4_55_4986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRECIPITATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic symptoms and plasma osmolality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Importance of osmotic diuresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abdominal pain in DKA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum ketones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - False negative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - False positive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serum sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pseudohyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serum phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serum amylase and lipase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Anion gap acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/19/24892\" title=\"table 1\">",
"      ADA criteria DKA HHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/3/35899\" title=\"table 2\">",
"      ADA DKA HHS water deficit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/22/36205\" title=\"table 3\">",
"      Precipitating factors DKA and HHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/17/27933\" title=\"table 4\">",
"      Metabolic causes acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=related_link\">",
"      Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=related_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25699?source=related_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_55_4987="Types of bariatric procedures";
var content_f4_55_4987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of bariatric procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Restrictive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vertical banded gastroplasty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Laparoscopic adjustable gastric band",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sleeve gastrectomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Malabsorptive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Jejunoileal bypass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biliopancreatic diversion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biliopancreatic diversion with duodenal switch",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Combination of restrictive and malabsorptive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Roux-en-Y gastric bypass",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4987=[""].join("\n");
var outline_f4_55_4987=null;
var title_f4_55_4988="Effect child parent obesity";
var content_f4_55_4988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of obesity in young adulthood by childhood obesity status and parental obesity status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Age, years&nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Number of obese",
"subjects/total number of subjects (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Not",
"obese in childhood",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Obese",
"or very obese in childhood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Neither parent obese",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;1",
"parent obese",
"       </td>",
"       <td class=\"subtitle3\">",
"        Neither parent obese",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;1",
"parent obese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        30/298 (10)",
"       </td>",
"       <td>",
"        28/101 (28)",
"       </td>",
"       <td>",
"        2/25 (8)",
"       </td>",
"       <td>",
"        6/15 (40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5",
"       </td>",
"       <td>",
"        23/298 (8)",
"       </td>",
"       <td>",
"        29/125 (23)",
"       </td>",
"       <td>",
"        8/34 (24)",
"       </td>",
"       <td>",
"        13/21 (62)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 9",
"       </td>",
"       <td>",
"        21/281 (7)",
"       </td>",
"       <td>",
"        23/132 (17)",
"       </td>",
"       <td>",
"        10/27 (37)",
"       </td>",
"       <td>",
"        20/28 (71)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 to 14",
"       </td>",
"       <td>",
"        24/317 (8)",
"       </td>",
"       <td>",
"        28/188 (15)",
"       </td>",
"       <td>",
"        7/11 (64)",
"       </td>",
"       <td>",
"        31/39 (79)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 to 17",
"       </td>",
"       <td>",
"        12/248 (5)",
"       </td>",
"       <td>",
"        26/187",
"(14)",
"       </td>",
"       <td>",
"        7/13 (54)",
"       </td>",
"       <td>",
"        24/33 (73)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Young adulthood defined as 21 to 29 years of age.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Whitaker, RC, Wright, JA, Pepe, MS, et al, N Engl J Med 1997; 337:869.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4988=[""].join("\n");
var outline_f4_55_4988=null;
var title_f4_55_4989="Diagnostic criteria for PSP";
var content_f4_55_4989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for progressive supranuclear palsy (PSP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mandatory inclusion criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Possible PSP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gradually progressive disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onset at age 40 or later",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Either vertical (upward or downward gaze) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No evidence of other diseases that could explain the foregoing features, as indicated by mandatory exclusion criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Probable PSP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gradually progressive disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onset at age 40 or later",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No evidence of other disease that could explain the foregoing features, as indicated by mandatory exclusion criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Definite PSP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clinically probable or possible PSP and histopathologic evidence of typical PSP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mandatory exclusion criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent history of encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alien limb syndrome, cortical sensory deficits, focal frontal or temporoparietal atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hallucinations or delusions unrelated to dopaminergic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortical dementia of Alzheimer type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prominent, early cerebellar symptoms or prominent, early unexplained dysautonomia (marked hypotension and urinary disturbances)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe asymmetric parkinsonian signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroradiologic evidence of relevant structural abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple disease, confirmed by polymerase chain reaction, if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supportive criteria for PSP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetric akinesia or rigidity, proximal more than distal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal neck posture, especially retrocollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor or absent response of parkinsonism to levodopa therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early dysphagia and dysarthria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Early onset of cognitive impairment including at least two of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Apathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Impairment in abstract thought",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Decreased verbal fluency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Utilization or imitation behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Frontal release signs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47:1. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4989=[""].join("\n");
var outline_f4_55_4989=null;
var title_f4_55_4990="CF infection control A";
var content_f4_55_4990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53301%7EPULM%2F63038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53301%7EPULM%2F63038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of infection control recommendations for healthcare settings for patients with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Category*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"9\">",
"        General principles",
"       </td>",
"       <td>",
"        Assume all patients with CF could have transmissible",
"pathogens and apply Standard precautions",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Implement transmission-based precautions according to",
"CDC/HICPAC published recommendations",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Healthcare workers should use approved methods of hand",
"hygiene",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gloves should be worn when caring for patients who require Contact or Droplet precautions",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Published recommendations for sterilization and",
"disinfection of patient care equipment should be followed",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gowns should be worn as defined by Standard or pathogen",
"specific precautions",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wall humidifiers and \"in-line\" and hand-held nebulizers",
"should be cleaned and dried according to manufacturer's",
"recommendations; disposable and single-use items should be discarded",
"after use",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In ambulatory care settings, examination room surfaces should",
"be cleaned after the room is vacated; regular cleaning of",
"other surfaces should be on a regular basis and as soiling occurs",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PFT",
"equipment should use disposable in-line bacterial filters in between each patient; disposable mouthpieces are",
"preferred; sterilization of the internal machinery of PFT machines is",
"not needed between patients",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Microbiology and surveillance",
"       </td>",
"       <td>",
"        Molecular typing using approved genotyping methods",
"should be performed as epidemiologically indicated",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory tract cultures should be performed at least",
"quarterly and processed for culture and susceptibility according",
"to CF-specific guidelines",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All Burkholderia cepacia complex isolates should be",
"confirmed and speciated at the Cystic Fibrosis Foundation Burkholderia",
"cepacia Research Laboratory and Repository (University of Michigan)",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surveillance strategies should be developed in",
"collaboration with the institutional infection control team",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CF: cystic fibrosis; HICPAC: Hospital Infection Control Practices Advisory Committee; MRSA: methicillin-resistant staphylococcus aureus; PFT: pulmonary function testing; VRE: vancomycin-resistant enterococcus.",
"     <br>",
"      * Categories are based on the CDC/HICPAC system. Category IA: strongly recommended for implementation and strongly supported by well designed experimental, clinical, or epidemiologic studies. Category IB: strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and a strong theoretic rationale. Category II: suggested for implementation and supported by suggestive clinical or epidemiologic studies or a theoretic rationale.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gibson, RL, Burns, JL, Ramsey, BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918. Copyright &copy; 2003 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of infection control recommendations for healthcare settings for patients with cystic fibrosis (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Category*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Ambulatory",
"       </td>",
"       <td>",
"        Encourage hand hygiene and have waterless antiseptics",
"or other products available for use by patients",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observe Contact plus Standard precautions for",
"epidemiologically important pathogens (eg, B. cepacia complex, MRSA,",
"multidrug-resistant Pseudomonas aeruginosa)",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop a reliable method for tracking patients' most",
"recent culture and susceptibility testing results",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alert other diagnostic areas of patients' transmission",
"precautions&nbsp;",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segregate patients infected with B. cepacia complex,",
"and",
"place patients with multidrug-resistant P. aeruginosa in room",
"immediately",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manage scheduling to minimize time in common waiting",
"areas",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discourage",
"use of common items in waiting area that cannot be cleaned between",
"patients (eg, toys, computer)",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Inpatient",
"       </td>",
"       <td>",
"        All patients with CF with B. cepacia complex, MRSA, or",
"VRE",
"should be housed in single-patient rooms that do not share common",
"facilities (eg, bathroom, shower)&bull;",
"       </td>",
"       <td>",
"        IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with CF, and without the above organisms may",
"share rooms with patients without CF who are low risk for infection&bull;",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients not on transmission-based precautions may be",
"evaluated for activity outside their hospital room as long as they are",
"educated according to hand hygiene and avoidance of direct contact with",
"other patients with CF, and with appropriate disinfection of surfaces.",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CF: cystic fibrosis; HICPAC: Hospital Infection Control Practices Advisory Committee; MRSA: methicillin-resistant staphylococcus aureus; PFT: pulmonary function testing; VRE: vancomycin-resistant enterococcus.",
"     <br>",
"      * Categories are based on the CDC/HICPAC system. Category IA: strongly recommended for implementation and strongly supported by well designed experimental, clinical, or epidemiologic studies. Category IB: strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and a strong theoretic rationale. Category II: suggested for implementation and supported by suggestive clinical or epidemiologic studies or a theoretic rationale.",
"      <br>",
"       &bull; Patients with CF who sleep in the same room at home may share a hospital room (Category II).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gibson, RL, Burns, JL, Ramsey, BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918. Copyright &copy; 2003 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4990=[""].join("\n");
var outline_f4_55_4990=null;
var title_f4_55_4991="MDI with counter PI";
var content_f4_55_4991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MDI with counter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5bnml8+T94/3j/EfWmedL/wA9H/76NE/+vk/3j/Oo6AJPOl/56P8A99Gjzpf+ej/99Go6KAJPOl/56P8A99Gjzpf+ej/99Go6KAJPOl/56P8A99Gjzpf+ej/99Go6KANrwpLIfENjmR/9Z6mvftEZ/tCksenrXgHhH/kYrL/f/pXvehf65STzitaZz19js4WJA5P51YVmx1P51Vh+6Ksp0rY85j97ep/OmFm9T+dKaT6UCGMzf3j+dNJb1P50r8UwE0gJEZv7x/OpQ7f3j+dQqakB4phcguWbH3j+dYd67c/M351tXPSsO970mVFmDeyNk/O351kyyPu++351p33U1lSdaRshBI/99vzp4kf++351FUi0AWI3fP3mz9auQO5x8zfnVKId6uwjkU0S2aNuzcfM351q25YYO5vzrMt61LbtVIzkzUtWbjk/nWtaluOT+dZVsK17XtVIykaduTxya0YCeOTWfAOlaMI4FBJbjJ9TVlCfU1XjqxHSKLMRORWhb5xWfF1FaFv0pMaLYPy1SP8ArqufwGqX/LakUXRnaKikYgGpB0qGb7poGYOuOVgc5PSvz+1u4lfWb5jI/M8h+8f7xr778SSbbGcnoEP8q/Pm7bfdTN6ux/WsqvQ7MH1G+dL/AM9H/wC+jR50v/PR/wDvo1HRWJ2knnS/89H/AO+jR50v/PR/++jUdFAEnnS/89H/AO+jR50v/PR/++jUdFAEnnS/89H/AO+jWjp0snkN+8f7394+grKrS03/AFDf739BQBRn/wBfJ/vH+dR1JP8A6+T/AHj/ADqOgAooooAKKKKACiiigDa8HHHiOz/3j/I17zon+uU+wrwTwiceIrL/AH8fpXvWh8ypWtM58RsdlB0FWVqrBnAqytanmseaUYAptNPFAhrnNRnrT2FMPWgB6VKKhSpRTArXPQ1h3vety66VhXueakuJgXx5NZUnU1qXvU1lydTSNUMFPSminqOaYMsxdauwDpVOIVftx0poTNC3FalsOlZ1uOlatsOlUjKRpWorWth0rMth0rWthVIyZo246VoRdBVCCtCEcCkSWo6sJUEdWEpFIsRda0IOlUIuorQg6UMpFk/cNUV/11XW+4apx/640ii72qCbpU/aq8vANIZyPjSTytFvn/uwufyU18AOcux9TX3l8SJPL8Las+cFbWUj/vk18GVlV3R24P4WJRRRWR2BRRRQAUUUUAFaWm/6hv8Ae/oKza0tN/1Df739BQBRn/18n+8f51HUk/8Ar5P94/zqOgAooooAKKKKACiiigDV8LnHiCyP/TSve9DP72P6V4D4cIXXbEnp5or3zRD++irSmc+I2O1g+6Ksiq0H3RVla2PNYtI3WlNNPNAhrVH3p7CmUAPSpR0qJKlFAFW6+6aw73vW5ddDWFfd6TLiYF93rLfrWne9TWY45pGq2GipUFRgVKo6UAWYRWhbiqMArRtx0qiWX7cdK1bYdOKzrYdK1bYYxVIyZpWy9K1bccVm2orVtx0qjJmhAOlX4RxVKAVei7UhIsx1YSq8fSp0pFFqLtV+CqEPUVfh7UFIsP8A6s1Ti/1xq45xGfpVS35lNSUWycjFV5uhqc8Cq8x4NAHnPxekEfgjWyf+fST/ANBr4Yr7a+N8pj8Ba0c8fZ2H518S1jV3PQwi9xhRRRWZ1BRRRQAUUUUAFaWm/wCob/e/oKza0tN/1Df739BQBRn/ANfJ/vH+dR1JP/r5P94/zqOgAooooAKKKKACiiigDc8J2Et3qsUq5EcBDM38hXt+hH95FmuA8EWqxaFG4HzSMXP54/kK7/Qv9YhrSmYYlWSO4t/uCrK9Kq233Fq0K2PMYtNP5U4000CGN0puac1NoAelSDpUaVLigCpddDWDe963brpWFfd6TLic/enk1mt1NaV71NZzdaRqhFHNTR9hUS81PEKaAtQitG3HSqMA6Vo245FMhmhbCta2HArMth0rWthwKoyZo2wrVt1wKzrUVqW46VRmX4ByKuxiqkI6Vcj6UgROlWFqBB0qdKRRYh6itCHpVCGtCHpSY0Sy8Rmqlt/rDVqb/VGqtp980ii4enFVZySCKtHpVW4PXFAHkP7QEoj+H2r47xgf+PCvjGvsH9o6TZ4Av/8AaKr/AOPCvj6sam56OFX7sKKKKzOkKKKKACilFLQA2tLTf9Q3+9/QVn1o6b/qG/3v6CgChP8A6+T/AHj/ADqOpJ/9fJ/vH+dR0AFFFFABRRRQAUUUUAeleApw+jxoT9wsv65/rXf6EP3qfWuS+Fnh95dKNwwJMp3j2HQV21lbm2vxGRjBzW0Uc1eV9Dsbb7oq0Kq2wwi9OatLWh57CmmnmmmgkjamHrUjVGaBkkdSiokqbtQBSu+hrCvu9bt30NYV73pFROfveprPbOa0LzqaoN3pGoi1YiHNQKKtRCmBbgFaNuOlUoF6Vo269KZmzQtlrVth0xWdbDpWrbjkVRmzRth0rUgHSs+2HArTgXpTMy5CKuR9KrQiraCkCJkFTKKjSpVoKLMI5rQhFZ8HWtCHtSY0PuP9UfpVay6mp7r/AFRqGyHBNIost0qpcHg1abpVO4+6aAPCf2mZSvgiVf70yD9a+Ta+o/2o5ceFYEz964X+tfLlYVPiPSw38NBRRRUHQFFFFAC0UlFADq0dOP7hv97+grMrS03/AFDf739BQBRn/wBfJ/vH+dR1JP8A6+T/AHj/ADqOgAooooAKKKKACiiigD6L+D1wsnhy2Ur82zb+XFdDqNv5eorJjkmvOvgfrA8h7VyN9u3T1Q//AF816zq0QmWOaPkVtHY4qz1sOteFFWweKqW33BVpTxWhxsceaaaWkPTFBJGx4phNPamHrQA+M1N2qGOpRQBUuu9YN93reu+hrBvu9ItHP3v3jVA9av3nU1RxzSNRyZJq1EORVeMVciFNCZbg7VpW46VRgFaVuOlNESNG2HStW3ANZ1staluOlUjJmjbCtKCqFsOlaUA4pkFyKrKcVBGKsoM0gJk6VKtRJUq0FFqGtCGs+AcitGEUmNDbs/uqjsSQh5qS9P7qoLN8KaRRZbvVK6Py1df7vFULo/KaBHzj+1O5/saxXt5/9DXzTX2b8VvCZ8T6BqeVDGGItHx0cDINfGbAqxB6jg1jUWp6eGacLCUUUVmdAUUUUAFFFFABWlpv+ob/AHv6Cs2tLTf9Q3+9/QUAUZ/9fJ/vH+dR1JP/AK+T/eP86joAKKKKACiiigBwxg5OD2ptFFAHW/DG8a18WW0YbC3IaI/iMj9QK+m9Exf6KD3HBr5C0mdrXVLSdDgxyq2foRX1l4FmG+WBj8snzKPrWtM4sWtmiaIFWKnqDirC9KtapbGOTzFGOcGqinj1rU4r3HcUhNBHrTcUCGseKZTyPWmGgCSOpR0qKOpR0oAp3fQ1g3vet676GsG+71JcTAvOpql3q7edTVPvQaksfarcI6VVjq7CORVITLsA6Vp246VnwDpWnbL0pozZo2w6Vq246VnW4wBWpbjAqkZM0betCHpVG37VoQjpQSW4+1WEqCMVZQcUholUetTLUS9KkWgZbg61firPg61oQ9KTKQy+/wBXUdoilM07UPuCltP9VSQx7mqF2flNX5DxWde/cOKBDLKzE3h7UC4zv3V+eXiGIQ6/qUS9EuZFH4Ma/SURC18NzZ4xESfyr82telE+uajKOj3EjfmxrCo7s9HCxsjPxS4paTNZnXZCEUlKTSUxBRRRQAVpab/qG/3v6Cs2tLTf9Q3+9/QUAUZ/9fJ/vH+dR1JP/r5P94/zqOgAooooAKKKKACiiigCW1BNzEAMkuP519R6OzQPFKnDLivmHTEMmpWqKMs0qAfmK+pNPTgg9jitKZyYrod2+2/slmjGQR8wrDeMxSFG4x3q/wCErtYrsWs5/cy8c9qva9pjRPJx+8jPzAdx2Na3OC3UwBihqdTT0piI24plPY0ygCWOpBUUVSjvQBTuzwawL7vW/d96wb7vUsuJz92fmNVR1q1d/eNU92DzxQalmIc1dgFZsc6A9RV6CdM9aoTNSDitO26ismCdPWtO3njyORTRm0bNv2rShOAKybeaPjDCrsdygYAkUzJm5ajgGtGGseC7iAHzCrcV9CMfOPzpk2NiM8VOhrHGpwL/ABj86eNZtgPv0hm2tSKawI9ftGfaJBmti1mSdQyEEUDNK361oxdKzrfqK0oulJlIr6h90U60H7oUl2N2BTrYYiFIY6TpVXyjNcRpjgnmrUvSptIh33DSEcDgUN2Vxxi5NJFL4iXo0rwFq9znaUtnI+uK/NeRy7sxOSSSTX6BftB3fleAru2U4MyPn6BTX59VzM9Wno2l0CiiikaBRRRQAUUUUAFaWm/6hv8Ae/oKza0tN/1Df739BQBRn/18n+8f51HUk/8Ar5P94/zqOgAooooAKKKKAClpKKANPw1j/hIdN3dPtMf/AKEK+n9L5L/7x/nXzJ4SAPibSwRn/SE4/GvpnRzkH61rTOPFdDXGUKsvBXnNegWkn9t6El5EA15ZjZMn99K4IDIrY8Jau2i6ukjc27/JKvqpq2jjg1ez2K+qWogmDx8wSfMp/pVE9K7rxBpkcNw8S4Nld/vIH7Kx6c+hriJ4mhlaOQEMpwc0J3CceVkDUw09+lMNMgkj6VIKjj6VIOlMCnd8isG+71u3WMGsK96GpZcTn7v7xrPkR5pRGnUnFaNzgvUmn24OoQHH8VBtHcs6f4KvLpFYZ5ro9O+G97Jj5q9B0OBVhi6DgV2WlCNcZIrm52d6hHseTw/Cm/kIIlxWlbfCO+6tcgV7XbPEFGGXNTgg9CKak+4ckex5Db/CacEeZegVoQ/CuMYMl834CvT6KfM+4ezj2PP4fhnYLjfdTH6Vfg+Hukx43GZ/qa7GjNF2Pkj2Och8GaLHz9mLf7zVNN4U0aSFo/saKCMZHWtzcPUUx54U+/LGv1YClcfKux87+NtBbQ/ETwwOxjPzLz2rp/BjytAA5Jqv8SL61vvFGLaZJQihSVOea0/CyBYhW1FtxdzzsakppI6q36itGKs6DrWhH0rVnMhso3OR2xRCMLUsKbpW9sUyMfLSKsNetjT4vKhHrWfbR+ZMOOF/nWrPItvbO56IuazqPodOGjq5voeNfHuf7Tpd+gPywwOv47TXwrX2z8W5C3hnUpX+80cjH/vk18TVNRWsjbCy5k2+4UUUVmdQUUUUAFFFFABWlpv+ob/e/oKza0tN/wBQ3+9/QUAUZ/8AXyf7x/nUdST/AOvk/wB4/wA6joAKKKKACiiigBR3pKWkoA3vA0Xm+K9NGQMS7vy5r6O0Nsxg14B8NIFk8RmVv+WMLOPr0/rXvehN+7Fa0zixR0cZ4ocU2M1J2rU4TtfDF2Na0WXR7g5uYVL25J5Yd1rE1WFpYPMI/fw/LJ6sOmf6GsqyuZbG8iubdiskbBlNdZrzJc20Gt2AHlzcTxdlfuD7GoejNk+aOvQ4txUVWrkJv3w/6snp3B9KgccZ/OqMhY+lPHSmx/dp3agRTuzwawb08Gt266GsG96Gky4mHN/rK1dEh339uP8AaFZU3+s/Gui8Ox/6dbHGfmFBqt0df4yvJtD0OW7t2IKR5rzLwF418XeLdbXT9OcL3dz0Qetd78ZPMg8J3OT8pjA4r5m0TXdS0G9lfSbp7d5R5bFepBrmSuenHzPoT4r634n8CPp4OsrOl0PvAY24615xrPxe8UWkqC11cTxsm7ch+77H3rqvjzOi6f4KS8X7QotQ8is2C2QO9eXeMF0izt4ksrW0MkkIkL28xkC5/hb/AGhSjsrlPyOg0n4weL724EZ1SVcnAx3r3DQrD4lXeirO2pW63Eqb44JpMSEfSvlvwJfWum61Z3N5FvhjnRn9lB5r60vvDWreIfidovijQ9XtZtBTyn2xzfMiAcjFEhxPGPEXjPxJYabfSXXiqS31S1kKPp77hJ1xwelYEPxK1qS3TzNT1V3I52ycZrrviffeFdQ1XxNrEljBdTLfm1G282yPkcOI+6gjk15z4Y8YX+lRJZWMFm0YY4aWJWYfiapCbsd38Lb3xZ488Tppgvb6KFRukmEjfKuepqj8c71vDnjObStB1XUJLeCNVlaaRuZO+PavYvAfjW60f4R6v4tntre6vYJhAiCMRgKCBhio6ZOa8d+JXiC9+IRsNR1uxgs7lcxoYkK+Ymc555NC3G9if4Pzz34mmuHaRvMABY5r6H8NLiKvDvhPpq2UQVM4ZyefpXu3h9cQmumn8J4+K/iG/B1rRj6Vn245FX416VTMUWLP/WS/QVAg+WrFl96X8Kbbx7nA7CpNGtEXbCLauT/k1T8ST7bUQqeZDz9K1kUIgHpXLatL5947ZyF4FZx96Vzqq/uqSh1Z5P8AGdxH4P1A/wDTF/8A0E18XV9ifHuby/Bt/wC8TCvjulV3LwnwBRRRWZ1BRRRQAUUUUAFaWm/6hv8Ae/oKza0tN/1Df739BQBRn/18n+8f51HUk/8Ar5P94/zqOgAooooAKKKKACiiigDu/hdFie/nP91Ix+Jz/SvadDOFrxv4Z8W9115lX+R/xr2HRTwK1gcWJ3OliPFWFYjBHaqsB4FWM1qcIrDNbHhvUUgeWyuz/odyNr/7J7NWOaYeOaTVxxdncl1OCTTdQmt5OVB7dCOxqvw3IPFad439p6WpPN1bDBPdk/8ArVgwy7JNjdD+lCGy+owtL2qRY2WIHqp70xs45oJKN10NYN73rdu+hrCvehpFxMST/Wj611nhmMm6t/rXKvzKK7bwnHuu7ce4o6Gl9UWPjdkeDpc9Tgc180W9mklwojjkllyCFRck19afFyyim8KDdbtcvvCmJe49a888G6TcaPG+oaTpZTVPuxoybuPXmuVSserFXOG+JPim28UX2lRX9nc6db2VssDh1+b3IBrz3xMNJg8hNGuJ5kOd/nKBj0r6N8aaLeeILSyvNW0x7nVQCkqeTjA7cgc1yD+D78yAW3g95OMZaE0RkNo8i8OrEsTtMrMCeMV7SfHGj+FvBUek+DPtD6hfxZvrt/lMeeqL/iK3vCHgPU5b+2GoeFxBZFv3h8nkD6V2kvgO5ay1Bf8AhHrYOvFnsjGW5/iz04pOQ0rHzXrtn4U/sk3NlqWoS6q8OZIXhAVJvQN3HvXF6ZC51GIurYByeDX1Nd/D3xE0f+h+HokkzzvCYqG1+GnjWVtr6ZYwIf4js4quZisYfwhuvHdtpd5/wimhx6lpUz4liugPKLe2SOa5XxVqmueJfiE6eILeK1ntQsH2eBMRxDPQYr6A0j4e6wPD62F4scLhixeG4Zcn12jiuVl+FPiiyvGlQQ3EAbJ2uoYjNJNvoN7Efh7R4tOuI44eVAzn616Noi4hNc3aadLbTnzIfK2jGK6nSl2wmuql8J4+K/is17ccjNX4xVC37VoJ0qzJE9ljEp/2h/KrVsg35A4HNVbPiOT/AHq0IFwo9+tZSdjpox5mvIj1GbybZiOp4FctL0JrY1aXzJQg+6tZFzwhqoKyIxE+eZ4X+0ZcCPwpcrnG4BfzIr5Rr6V/aXucaKIxj55VH9a+aqzqbnZhVamFFFFZnQFFFFABRRRQAVpab/qG/wB7+grNrS03/UN/vf0FAFGf/Xyf7x/nUdST/wCvk/3j/Oo6ACiiigAooooAKKKKAPRvhxH/AMS92A5MpyfwFer6NwcV5J8M7qPypLYsBIH3YPcHHNex6dDhVcdDWsDixBuwHirANVoegqyvatTiF7UGilPNIQ63maCYOvbqPUelZ+rQCOXzI/uPyKtmlYCaExN9QaBo0NBkW50xo3++h21TlXYzA9jVfQJja6iYmOBIMfiKvX4AmbHehAzJu+hrCvehrcus4NYd70NIqJjkDzR9a7/wRg30GR0NcFj96PrXe+DvkuIm+lPdFXs02e8adDazQLvijZv9pc1oJbwp9yGNfooFczpupRwlVlO1vQ10MN7byqCsq8+9cqTPUU4vqWQAOgAopolQ9HX86XcvqPzpjuhaKTcPUUuR60BdBRSbh60bh60BdC0U3eO1RzSOI22L82OCadhOaSuzz7XpQ+qXKoBtV8cVPp4/c1oXelIYnfH70tkn1NV4YjEgU9a3pR5Y2PKry56jki5AORV6PhapW45q6vSrZmi1Yruj4HV6vXDiGFm9qraWuYlb3NM1SXLBB261i/elY7Yv2dLm6szJCWYk9TVC+OENaJXis7UeIz9K1ONny5+0xPlbWMH7038hXgVe0ftH3ccmq2kCsC4Znx7dK8XrCfxHqUFamgoooqDYKKKKACiiigArS03/AFDf739BWbWlpv8AqG/3v6CgCjP/AK+T/eP86jqSf/Xyf7x/nUdABRRRQAUUUUAFFFFAFixu5rG6juLZykiHIP8ASvfvh34ut9Ssk88ANjDD0NfPNdR8P7tbfWxG7lRMMDnvVRdmZVYc0T6kg+zT4MUgAqwLR2J8sBwPQ1xFpBdCJXtZs5HerK6nq1p9+38wDuprbU81xOraCVD8yMPwppQ5wRzXNr4zaE/6TDcIR3xmrUXjmxk4acqT13rRcnlZrleKjIIPHUVXj8TadOoHnwH8s1ah1PTnOWEbj/ZkxRcOVkF6pXZcx8MhBNaN4yyhJEOQyg1keItR02HT2a2u/Lcn7knP6itCytpl0S0kfEmUBLr056ChMbWhn3XQ1iXY65rau+9Y9yOtMSMlh+8yK7/wJcW81zDHM6oQerd64V8buKt2khjIKnB9qaQNnuN9MJbzJ2/KMcVoWU6Kozg143aavcoABK351r22tXXH7w0+Unmd7nrKXG45HSr8NyQvQGvLLbW7nj94a0odauCBiQijkF7Q9JWYntUokNefxavcMMGRquRapOesh/OlyFqs+52ysxNSbHNcampTDo7fnUi6jOf+WjfnU+zZrGuup16Iy9W4p0mwj52A/GuR+2ynq5/Oka7bu/60vZPuWsVFKyR0F68KLiPDMffgVhTKxlJOPwqs92gXLOMD3qD+1LYc+apHTrWsYNHLOak72sbEAFWf4ayrDUba4bakg3dge9bAjIQljtH86TVtwWuxZsZ2SMR7CRjO7tUM7JvZnbmvP/EM+rjxAiadceXAyDIIzzmozp+pXf8Ax9387D0U4FSo9S5VW0k+h1+oavY2YJmuI1I7Zrzbx94/h0/S7ma1jdwiM2cegrej8PW8fzOu8+rHNeZfHK4g03wxdhQqsYygHueB/Om9FcKfvSSZ8z+JtcuvEOrzX963zuflXsq9gKyaKK5T2EraBRRRQAUUUUAFFFFABWlpv+ob/e/oKzgM1paaP3Df739BQFihP/r5P94/zqOpJ/8AXyf7x/nUdABRRRQAUUUUAFFFFABT43aORXjJV1OQR2NMooA9t+HPjeK8jS0vmCXK8HPAb3FeqW0yuoZSGBFfIMbtG6ujFXU5BBwRXpXgr4jy2RS21di0fQTf4/41rGfRnHWw/wBqJ7rJbQyA741P1FZ9xoVhPndbx/lRper21/AksEqsjDIINaG8Y9a0OLVHNXPhCwk+6hT/AHTisybwYgP7m4mT6NXblvpTSaNBqTOFTwUZZlNxdTOgI4Jr0iwmexgRIT8gAG08g1VQDGalJ+WiwnJvclvLrTrgHzoHgk/vRnI/KuRvriIzyRwP5ijo2MVq3p4auW8PSW02szQ3LhQWwCaumle7HbmQ5GYkjHSpzIeCq8DrV3V7WCxmykqsp9DVJHiYAhxXWlF6mTi1oXoL5McxdKmGpHcNke3HXNU4kjJwHGasJEpHJFNQiJpl+DVpOyirkesTqAdgrNitwm1lI5qeW3kZPkI/CnyR7E2NJNfuf4FXIqxB4juyfuLx2rFhtHx8x5q5BYNj5OT0p8kewuU2Y9cvmPAUCmSeIrtCVJGfWktLCV4yAh461O/h+QkEr1FK0FuVyPoVZPEF6xwj8Un9q3bRMHnJYnpV+18Mys4IJrUh8KKjnecnrnNDnTQKlN9Dl1u7g5VpXIPvVpRujVUVie9ddF4ZtVt/OeSJQPvbjVm7i0TSLaO4e7hZS2CoIJz9KTrx2RccNLdnM3Gn3dvpxuQGjKjKnoRXoWk3LXWkW07nc7Rgk++K8z8aeNlu7V7S0UBAMbh3r0Dwz8vhiwz18kGsq13FOQtFK0SP7P5l0spwAcgevWrmxQMAVTszunJ68VZvrqG0gaWdwiKM81zlFTU7iO1tnllYKqjNfHHxx8ZL4g1xrKzk3WluxLMDwz+n4V2Pxx+LTXck2jaDLgAlZZlPT2HvXz+Tkkk5NY1JdEd+Go29+QlFFFZHYFFFFABRRRQAUtJRQA5TitLTm/cN/vf0FZdaWm/6hv8Ae/oKB3KM/wDr5P8AeP8AOo6kn/18n+8f51HQIKKKKACiiigAooooAKKKKACiiigDa0LxJqWjOv2WcmIHPlNyv/1q9a8K/Ea1vwsVyfJn/usev0PevC6UcdKpSaMp0oz3Pq+21OG4UFHFWN+SMHIr5p0TxbqOllV8wzQj+FzyPoa9E0D4hW1wUSWTy5D/AAycfrWimmcc8PKOx6yjfLUwOUrnNP163uFXLjmtyGZZEypBzVo52mipfH5WNeU3UxS+maMkNvPIr1S/I8tvoa8juW3XMx9WNaUikRX2rXWfmlYgds1TTXLhSMMcVX1F8nHes4Z71rzNGygnqzpIvEVwv8Zq5B4nnXqxNcrGuetWIlB6U1Ng6UTtE8WTFBgdK0IvGLoFA59c1whZYkLOeKNL87UrwRWyFjnGB3p89tyPZrdHoi+O1Tkrkmp4/iR5WWWLkHg4rU8I/Cma4C3OpZRG52kV6fpHw10I4ilSMn3ArN1DO6vZHlVj8VZVlJKKqsc4IxWi3xEvbmZpYQgUjAFeqap8HtBubbEKIrgccV85/EXwdrPgO+kuoQ1xpm75sfwCiNWLexq4yWh28fjzVF/1UgXP6VBceM9bkB23TLkYyDXFeH9Qt9XhDRsA2Ola00YVQCTxW6UdzO7Lk2sajJhpruVt3ON3GahlvZSEEsjHPvVRmHCkYoDAkOV6HrVpESdzRmlDRjBOTX0RoTlPDFj6eQOfwr5zdjIgPevWvGPjew8H/DyG6uZAZzbhIYgeXcjgCssTpFGVNOU7I15/EVhpFjLdXU6AjPU9MV81fFn4w3euyy2GiytHa8hplOM/7v8AjXn3ivxpqniImOeUxWuciFDwfqe9cvXnSqX2PUo4ZR1kKSSSSSSepNJRRWZ1hRRRQAUtJRQAtJS0UAJRSmkoAK0tN/1Df739BWbWlpv+ob/e/oKAKM/+vk/3j/Oo6kn/ANfJ/vH+dR0AFFFFABRSgDaeefSkoAKKKKACiiigAooooAKKKKACiiigDS03Wb/TmBtrhgo/gblfyrv/AAp8RmjmSC+XYG43A/Ln+leXUU02iJ04z3PpAeIYLmJirg7lI4NcBI++R2Xpk157pd3cwXcK280iAuBtB4PPpXfjasZOck9a6qDvc4qtL2Zk6iwLdeaoqfWprxsyHioVHtWrKWxOhq7AB1qmnQYHWrch8jT5ZD2FMUmZGqX3mTFUPyqfzr3r4FaDawQHVb+IGQjKKR0r5ttW869hQ8h5Bn86+ufC9u9v4ethEuF2DpWPNzCr3gkkdffay7sUhwq+1VoLiViSXbP1rPgidq0reBgDmnaxwt3NKy1CeJgRI2PQmtLVLW18R6NPaXkavvQryKx4YW9q0rHdFIMkUhps+MbyCbwd48vNMJIiWU7M+h6V6K0izQpKMncOa4b4+XMc3xPvWg/g2gketdVoLmXw+js3TAHvW9CV7rsdNZfDPuidsgeuelMVjtYNnGasKDgN26HinmMeWGkGcnt3roMLE9sCYwy9xxmvG/H+v3+t67Kt9KzRWrGGGPPyoo4/M+texWykNtGdnUCvB/EP/Idv8g/69/51zY34YnRgUueTM6iiivOPTCil7UlABRS44pKAFpKKKAFpKKUDJoASiiigArS07/UN/vf0FZtaensTAcknDYH5CgChP/r5P94/zqOpJ/8AXyf7x/nUdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAWdOAN/bg5x5i9PrXoDEbWx07V55aOI7qFz0VwT+dd7If3TFTxiurD7M5MT0Midi0ppV5X6VGT8596cvXrW5KLEbdiOlXbqPztFmxycVRiLcCtrSlWaJ4W/iFNK+hnUdlc84icwzKw4ZGBr6j8A6/wD2n4ctvLlzhRlc96+cdZ0x7e7lTGCDx7itDwb4rvPDF6OGe2Y/PGf5iuWzg7M3qx9tG8dz6qt5XGMMa0oJGOMsfzrzrw14/wBG1OJStykchHKOcGuvg1vT8bvtURH+8K1TTPNlCUXZo6OJz6mq/iDXbfQNEur+7kCJEhIyeprkNZ+IeiaTEzNcrJIOiIck14L8SfHN94suPLJaKwQ5WIHr7mk72LpUXN67HLarfS6/4kuLyTJkupi2PbPA/KvY9OhS30GGJhh85rz34ceH3vdR+1yofJi5yR1NeqXMhgkWNQjKo6EdzW1CLjG76m+JkpSUV0KAbavzOdpHAx0pySZcbz8pHFDrvJaU7Se2KjZFidlhYuvYkV0HPqW7ZyzZiJG04JNeEeIjnXdQOAMzv0+te6WrbJUHynJHIFeF6+rf2xfOQdpuHG73zXLjPhidOC+OXyM+koorzz0RaSlpKACilJzSUAL3o6mkooAKUnNJRQAUUUUAFaWm/wCob/e/oKza0tN/1Df739BQBRn/ANfJ/vH+dR1JP/r5P94/zqOgAooooAKKKKACiiigAooooAKKKKACiiigAopQCTgDmgjBwetACUUUUAFdhpNwbjSFLHLJ8h/D/wCtXH1raHex2wnimYqsgBB9CK1oy5ZamVaPNHQ03XqRQgPfp7UwyJtyGBB5Bp6TIT99cjgjNddzAswZznpWhZTGCZX6CqNvKrDII/nVgHIyORTTJkrqx2d/4YTxDpS3NljzwOCP4vavO77Sbm1naG8hKspwdw6V2XhzXJ9MfajEwk5ZAf5V6DBeeH/E1njUEUTLxvHDj60733Mk3HRHg406JcMrJu+hFWViuUZUaV1DDg7zjFexXXw0t5ozNp19HJGegYYNYx8BXqs3ERVep3VcYJ7MmVVrdHmJsZGYj72D19a19B8KXGrXKRhSEByzY4Ar0G28HpAy/apFJ7AHr+NX21TT9IieGHG/HCoRj8TVOMUSqsn5DRBb6DYQ29oo29MkfePrWe8UkgkZsgk7ic1DPq8Vy6PPKnJwATwoqWO/trnzY1uo0CLuLM3XFO9ibXJ2CssXmEZA4p8SkHCod5PJBrIuPENlHKcSJINuPlWopvFNjZXEcd2JIPNDYdxgLxkfgaHJJXZSi29DoUj2ugBCr3YjrXz/AKy4k1a9dDlWmcg+vJrptb8c3l3BPbWsawRuSC4bLbfb0rjSTjGeBXDiKyqWUeh24ei6bcpdRKKKK5TqCiiigAopaSgAooooAKKKKACiiigArS03/UN/vf0FZtaWm/6hv97+goAoz/6+T/eP86jqSf8A18n+8f51HQAUUUUAFFFFABRRRQAUUUUAFFFFABTiRtUBcEdTnrTaKAHpIyBtvBYYJptJRQAtJRRQApFKVIUE9DTaKAN7w20cztazKGzyPp3qnrdmLO8cKcAnIU9RVCN2jYNGxVh0IODSyzSSyF5HZ3PUscmtOe8eVojktLmQK0qKGUuq54IPetvR11NJo7kwTzWwGWGcAqeO9YOTjGTjrin+bIBgO2MYxnt6VKlYpq50zabr6zMdjxBm4DuOAauw6fq6uyG4jDrnLeYADj0xXIG7uCADPKccj5zxTPtE2MGV8em41pGrYzlTuem6Zc+JbaKRINWjSNBuKvKCOfT1qYXOvTMN2s28bMCP9ZgYHvXlnnP/AHmznI+Y8UCVznc79OOar2/kR7A9PntL24hjkufEMRUjIXeeD0x+lRLo9uSfM161DccDJBrzIsSepoBxnv6e1P6x5D9gj1aLQ9HcLv8AE1qowd2YyMH0HrSR6VoYlVZPEKImRl/KB4+meTXlZO7aM9OOaH2gKFzkZ3HPB57UfWH2D2CPWbWx8PLLG0viAbVkAZVjGSM9R/hWD8Wr+xvdStzp0gkjBc7hjpkY4HT6Vwfy7T13UFiUVeMAkjipnXco8tgjQUZKQ2iiisDcKKKKACiiigAooooAKKKKACiiigAooooAK0tN/wBQ3+9/QVm1pab/AKhv97+goAoz/wCvk/3j/Oo6kn/18n+8f51HQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTixKgE8DpTaACilzmkoAKKKKACinoVBO9Swxxg45plABRRRQAUUUUAFFFFABRRRQAUUUUAFaWm/wCob/e/oKza0tN/1Df739BQAk1hmaT95/Ef4ff60z7B/wBNP/Hf/r0UUAH2D/pp/wCO/wD16PsH/TT/AMd/+vRRQAfYP+mn/jv/ANej7B/00/8AHf8A69FFAB9g/wCmn/jv/wBej7B/00/8d/8Ar0UUAH2D/pp/47/9ej7B/wBNP/Hf/r0UUAH2D/pp/wCO/wD16PsH/TT/AMd/+vRRQAfYP+mn/jv/ANej7B/00/8AHf8A69FFAB9g/wCmn/jv/wBej7B/00/8d/8Ar0UUAH2D/pp/47/9ej7B/wBNP/Hf/r0UUAH2D/pp/wCO/wD16PsH/TT/AMd/+vRRQAfYP+mn/jv/ANej7B/00/8AHf8A69FFAB9g/wCmn/jv/wBej7B/00/8d/8Ar0UUAH2D/pp/47/9ej7B/wBNP/Hf/r0UUAH2D/pp/wCO/wD16PsH/TT/AMd/+vRRQAfYP+mn/jv/ANej7B/00/8AHf8A69FFAB9g/wCmn/jv/wBej7B/00/8d/8Ar0UUAH2D/pp/47/9ej7B/wBNP/Hf/r0UUAH2D/pp/wCO/wD16PsH/TT/AMd/+vRRQAfYP+mn/jv/ANej7B/00/8AHf8A69FFAB9g/wCmn/jv/wBej7B/00/8d/8Ar0UUAH2D/pp/47/9ej7B/wBNP/Hf/r0UUAH2D/pp/wCO/wD16PsH/TT/AMd/+vRRQAfYP+mn/jv/ANej7B/00/8AHf8A69FFAB9g/wCmn/jv/wBej7B/00/8d/8Ar0UUAH2D/pp/47/9etDT7HELfvP4v7vsPeiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some metered dose inhalers have built-in dose counters. When the counter reads 0 (zero), there is no medicine left in the inhaler.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_55_4991=[""].join("\n");
var outline_f4_55_4991=null;
